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Abstract
Background: Glaucoma is the leading cause of irreversible blindness. The last
decade has seen the emergence of minimally invasive glaucoma surgical procedures,
with the most recent utilizing implantable devices. The first generation of
micro-incisional devices has been made of titanium. Since then other materials have
also been introduced.

In each case, the presence of a permanent foreign body has

been associated with undesirable wound healing responses characterized by fibroblast
proliferation and surgical failure. Magnesium alloys have attracted much attention as
biodegradable implantable materials due to their excellent biodegradable and
biocompatibility properties. The purpose of this research was to evaluate the in vitro
biocompatibility and anti-proliferative properties of differently coated magnesium
alloys in a primary culture of human Tenon’s capsule fibroblasts (HTCFs). The goal
of the research was to establish a proof of principle for further exploration of this
novel material as a potential adjunct to glaucoma surgery.

Materials and Methods: Pure magnesium was cut into discs measuring 14.5 mm in
diameter and 1 mm thick. These were coated with Hydroxyapatite (HA), Dicalcium
phosphate dehydrate (DCPD) and Dicalcium phosphate dehydrate + Stearic acid
(DCPD+SA), respectively. Coated magnesium alloys were immersed in simulated
aqueous humor to examine the corrosive properties, the released ions, and the
variation of pH. The primary HTCFs were seeded on DCPD, DCPD+SA and HA

i

disks in 24-well culture and incubated at 37 degrees for 2-7 days.. Glass disks were
used as control. The MTT and LDH assays were used to determine cellular metabolic
activity and cytotoxicity during the logarithmic phase of HTCFs, respectively. The
BrdU assay was used to evaluate cellular proliferation. Western blot was used to
assess the expression of alpha-smooth muscle actin (α-SMA).

Results: A total of 453 coated magnesium alloy disks were evaluated. Corrosion was
observed in 67 disks (14.8%). The corrosion rate of HA (12.6%) was lower than other
two coatings (DCPD 15.9%, DCPD+SA 15.9%, respectively), but the difference was
not statistically significant different (p=0.851). The immersion test showed that the
HA coating had better ability to prevent the coating dissolution and corrosion. The
cellular metabolic activity of different coated magnesium alloys gradually declined
during the logarithmic phase of HTCFs, and each type of coated magnesium alloy
demonstrated significant decreased metabolic activity of HTCFs when compared to
the

control (p<0.001). The cytotoxicity of different coated magnesium alloys

slightly increased during the logarithmic phase. The group of DCPD+SA showed
higher cytotoxicity than the other coatings, but it was not statistically significant
different when compared to the control (p=0.976). Significant inhibition of
proliferation was observed with the DCPD+SA coating (p=0.47). The expression of
α-SMA was decreased in the cells when seeded on all of the coated magnesium alloy
disks.

ii

Chemical coatings are able to affect the corrosive properties of magnesium. HA was
the most resistant to corrosion. No significant difference was found in metabolic
activity or necrosis at different times during the logarithmic phase of HTCFs.
DCPD+SA demonstrated a stronger ability to reduce metabolic activity while its
cytotoxic profile was the same as the titanium and glass controls. In comparison to
titanium, coated magnesium alloys attenuated HTCFs proliferation. Coated
magnesium alloys reduced the expression of α-SMA. The expression of α-SMA was
significantly decreased in cells exposed to the HA coated magnesium

Conclusions: Different chemical coatings on magnesium were able to affect the
corrosive properties which, in turn, influenced the morphology and function of human
Tenon’s capsule fibroblasts. These results support the further study of coated
magnesium for its potential modulatory role in Tenon’s capsule wound healing.

Keywords:
Glaucoma, glaucoma drainage device, fibrosis, tenon’s capsule fibroblasts,
biodegradable, magnesium, magnesium alloys, coating
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Review

A feasibility study of using biodegradable magnesium
alloy in glaucoma drainage device

Abstract
Technological advances in glaucoma have challenged the traditional treatment
paradigm.

Historically, incisional surgery has been used in cases of advanced

disease and/or uncontrolled intraocular pressures resistant to medical or laser
interventions. Despite these trends, surgical manipulation of the tissues and
unpredictability of wound healing continue to result in surgical failure. Magnesium is
an essential element for the human body and plays a critically important role for
maintaining the functional and structural integrity of several tissues, including the eye.
Due

to

several

of

its

advantageous

properties

such

as

non-toxicity, biodegradability, and high biological compatibility, magnesium alloy has
attracted great attention as a novel biomaterial. Biodegradable cardiovascular stents
made of magnesium alloy have already been introduced into clinical practice. The
purpose of this review is to determine if bio-absorbable magnesium alloys can be
utilized as a promising candidate for the development of a new generation of
glaucoma surgical assistive devices.

Key words: Glaucoma, Tenon’s capsule fibroblasts, fibrosis, Glaucoma drainage
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devices, Magnesium alloy, Coating, Anti-scarring.

Introduction
Magnesium is an essential trace element for human life, and also is one of the most
important regulatory cations involved in several biological processes. Magnesium is
the second most common cation in the intracellular fluid. Mg2+ plays a crucial role in
regulating vascular functions and energy metabolism as well as maintaining water and
electrolyte balance1,2. The level of Mg2+in the serum ranges from 0.8 to 1.2mmol/L,
with homeostasis being maintained by the kidney and intestine. Hypomagnesemia
(serum Mg2+<0.8mmol/L) has been suggested to be associated with several disorders,
such as vascular spasm and arrhythmia. Magnesium deﬁciency may also lead to
cardiovascular, respiratory, and digestive illnesses, as well as abortion, fetal
abnormalities and other obstetric diseases3. A large number of studies have shown that
dietary intake of magnesium can prevent osteoporosis and femoral neck fracture

4-7
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and help to manage diabetes and coronary artery disease8,9. Serum Mg2+ levels
exceeding 1.2mmol/L may cause muscular paralysis, respiratory distress and
hypotension10; however hypermagnesemia is rare due to the efficient excretion of the
element in the urine11.

Glaucoma is the second most common cause of blindness and the leading cause of
irreversible worldwide blindness12. Surgery is an important treatment option for
glaucoma Incisional surgery, with and without glaucoma drainage devices, is a major
part of the treatment paradigm when medical options cannot be tolerated and/or fail to
xv

reach a pressure that halts progression. Long-term complications are often related to
variability in the wound healing process. Devices used adjunctively in surgical
glaucoma management represent a foreign body under the conjunctiva, causing
fibroblast proliferation. This may be due to the persistent effect of inflammatory
mediators and cytokines at the level of the conjunctival-Tenon-episcleral interface
resulting in fibrosis and obstruction of the fistula13,14. There continues to be
significant interest in adjunctive approaches to minimize scarring in the
subconjunctival space, reducing inflammation, and in slowing or halting the excessive
fibrotic healing process.

Bleb scarring is a major contributor to increased intraocular pressure (IOP) and
surgical failure. In order to improve the success rate of glaucoma surgery, various
intraoperative anti-metabolites have been used to inhibit fibroblast proliferation, such
as 5-fluorouracil (5-FU) and mitomycinC (MMC). However, these antimitotic agents
interfere indiscriminately with cellular proliferation, and can contribute to a number
of postoperative adverse events, including bleb leaks, hypotony, choroidal detachment,
endophthalmitis, and keratitis15,16. There continues to be a significant need for a safe,
non-toxic, and effective approach to reduce postoperative scarring and adhesions after
glaucoma surgery. The relatively recent introduction of bleb-forming micro-invasive
glaucoma surgery has heightened this interest.

Magnesium alloy is a biodegradable material which possesses many advantageous
xvi

properties such as high strength, light weight, and high biological compatibility.
Additionally, magnesium alloy has been shown to be able to reduce irritation and
inflammatory reactions in the body17-20. We were thus motivated to determine the
feasibility of developing a magnesium-based bio-absorbable device for modulation of
wound healing associated with glaucoma surgery. Moreover, the possibility that the
slow release of Mg2+ by the device could have a local neuroprotective role is an
intriguing concept worthy of future investigation.

Application of magnesium alloy in modern medicine
The application of magnesium alloy as a bio-absorbable material in clinical practice
can be traced back to the early 1900s. The first use of magnesium was reported by
Lambotte et al. in 1907, who utilized a plate of pure magnesium with gold-plated steel
nails to treat a fracture involving the bones of the lower leg.

The initial attempt

failed as the pure magnesium plate corroded too rapidly in vivo, disintegrating only
eight days after surgery and producing a large amount of gas under the skin21,22. In
1938, McBride et al. developed magnesium alloy fixtures which successfully treated
20 cases of fracture without any significant adverse effects, and the fixtures were
completely absorbed three months after surgery

23

. In 1944, Troitskii et al. applied

cadmium magnesium alloy as an internal fixation device to secure the bones of 34
consecutive fracture patients. They observed that the fixture could maintain the
mechanical integrity up to two months, and it was completely absorbed after 10-12
months. Nine cases were unsuccessful, and these failures were attributed to infection.
xvii

A hard callous was found around the fracture site with no increase in serum levels of
magnesium and no obvious inflammatory reactions to the implantin all 34 patients
who were studied23. Znamenski et al. reported similar results in 1945, where
magnesium alloy containing 10% aluminum (Al) was used to treat two patients with
gunshot wounds. The magnesium implant and nails were completely absorbed after
4-6 weeks23. These early reports demonstrated that magnesium alloy was a non-toxic
biomaterial, and it had the ability to promote bone healing. However, due to its
characteristics of hydrogen emission and low corrosion resistance in the electrolytic
and aqueous environments of the physiological system, biomaterial research on
magnesium alloy was suspended. Thereafter, stainless steel materials were widely
applied in bone internal fixation devices. Until recent years, with the use of advanced
techniques,

more

complicated

alloy

compositions

have

been

introduced.

Advancements in corrosion protection technologies have effectively reduced the
production of hydrogen gas. It is for these reasons that interest in the medical use of
magnesium alloys has once again increased.23.

Numerous in vitro and in vivo studies have focused on the use of magnesium alloys in
internal fixation devices for fracture repairs. The corrosion resistance of different
types of coated magnesium alloys has been studied in cytological and animal
experiments to determine the reduction in hydrogen evolution and tissue compatibility
24,25

. In vitro experiments confirmed that there were minimal cytotoxicity and cell

apoptosis when fibroblasts and osteoblasts were exposed to various coated
xviii

magnesium alloys25. In vivo experiments found that Mg2+ could enhance bone
formation during the degradation process of the implant, and no inflammation was
observed26,27. F.Witte et al. successfully implanted magnesium alloy stents into the
femur of rabbits, and the magnesium implants substantially degraded after three
months. Their study also showed that the degradation process of the magnesium alloy
stents could promote trabecular bone formation and resorption, without any
significant harm to their neighboring tissues. They concluded that even fast-degrading
magnesium alloy stents could show favourable biocompatibility thus establishing a
more convincing potential role, in musculoskeletal surgery28,29. In addition, F.Witte et
al. also carried out an in vitro experiment to investigate the properties of a metallic
matrix composite made of magnesium alloy AZ91 as a matrix with hydroxyapatite
(HA) particles as reinforcements. The results revealed that the HA particles could
stabilize the corrosion rate of the magnesium alloy, and this biodegradable metallic
matrix composite HA was a cyto-compatible biomaterial with adjustable mechanical
and corrosive properties30. Okazaki M et al. developed a novel material containing
magnesium, calcium, and phosphate for use as oral implants. They found that
magnesium increased the metabolic rate of osteoblasts31. Zreiqat et al. found that the
protein levels were significantly higher in human bone-derived cells cultured on
[Mg]-Al2O3 (alumina doped with magnesium ions) compared with those grown on
Al2O3 alone32. Hunt Jet al. reported that the magnesium-coated Ti-6Al-4v implant
could activate bone cell signal transduction and hence improve protein synthesis and
accelerate bone formation33. The mechanical and degradation properties of
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magnesium have been used to develop novel cardiovascular stents, so as to maintain
the endothelial function of coronary arteries and to reduce the risk of coronary
ischemia and occlusion34-37. Based on a large number of clinical trials38,39, magnesium
coronary stents have been introduced into clinical practice40.

The important roles of Mg2+ in the eye
Mg2+ is important for maintaining the structural and functional integrity of several
vital ocular tissues such as the cornea; lens and retina. The concentration of
magnesium in aqueous humor is 2.97 ± 0.75 mg/ 100 ml. The magnesium levels in the
lens are far higher than those in the anterior chamber and vitreous body. The
concentration in the lens periphery is four times greater than the axial regions41. Mg2+
plays an extremely important role in maintaining retinal function. The reason for this
is because magnesium acts as a co-factor involved in the catalytic function of more
than 350 enzymes in the body and regulates neuro-excitability. Membrane associated
ATPase functions that are crucial in regulating the intracellular ionic environment, are
also magnesium-dependent. As a result, a reduced level of Mg2+may affect the
functions of Na+/K+ ATPase and calcium dependent ATPase, causing an increase in
the intracellular concentrations of calcium and sodium as well as a decrease in the
potassium42 concentration. Such ionic imbalances induced by magnesium deficiency
may contribute to the pathogenesis of many eye disorders, such as cataract, corneal,
conjunctival, choroidal and retinal diseases43,44.
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Maintenance of corneal structure and function
Mg2+ is one of the most important cations in the cornea as it is involved in the
metabolism and maintenance of corneal transparency45. As early as 1920, Kirkpatrick
et al. reported the use of magnesium sulfate in the treatment of keratitis, conjunctivitis,
and corneal ulceration46. In 1985, Bachman and Wilson performed an animal
experiment and found that the epithelial surface of the excised rabbit cornea was
maintained best with a buffered solution containing Mg2+, K+, and Ca2+ 47. Hogan et al.
reported that Mg2+ loss in the corneal stroma was associated with corneal edema48. In
2001, Gong et al. investigated the effect of magnesium deficiency on the cornea in
rats that were fed a low magnesium diet for 3 weeks. Their findings revealed that
magnesium deficiency affected the structural and functional integrity of the cornea49.

Keratoconus is defined as a progressive eye disease which causes thinning and
fragmentation of membranes, degenerated cells and collagen fibers, swelling of the
mitochondria, and biochemical abnormalities in protein synthesis and expansion of
central area of the cornea. Thalasselis et al. reported that hypomagnesemia was
commonly seen in the serum samples of keratoconus patients, and magnesium
deficiency could pathologically affect the integrity of the cornea50. Prior studies also
showed that magnesium deficiency was associated with a reduced number of
microvilli and their irregular arrangement. Vesicular degeneration and swelling of the
mitochondria were observed in the cytoplasm of epithelial cells, resulting in abnormal
apoptosis of thesecells51,52. Magnesium deficiency was also associated with rupture
xxi

and fragmentation of the Bowman’s layer, which may be an early change leading to
keratoconus53,54.

Supporting lens metabolism and preventing cataract
Cataract is the most common cause of blindness worldwide. It is characterized by
progressive lenticular opacities. It is known that cataractous lenses have an abnormal
intracellular ionic environment with lower concentrations of potassium and
magnesium and higher concentrations of sodium and calcium relative to the cytosol of
most cells. The lens membrane has increased permeability in the presence of a
cataract55. Studies have explored he relationship between magnesium deficiency and
cataract. These studies have shown that the alterations in lenticular redox status and
ionic imbalances form the basis of the relationship between magnesium deficiency
and cataract. It is believed that Mg2+ plays an important role not only in maintaining a
low lenticular Ca2+ and Na2+ concentration but also in preserving the lens redox status,
which has been shown to reduce lenticular oxidative stress56,57. Nagaiet al. reported
that the incidence of cataract was significantly lower in Shumiya rats fed 200mg/L
magnesium compared to controls. It was noted that the intracellular Ca2+ level of the
lenses was also significantly lower58. Based on these findings, they concluded that an
appropriate supplementation of magnesium could delay cataract genesis, probably by
inhibiting the increase in Ca2+ levels in the lens59. After a thorough literature review,
Agarwal et al. concluded that magnesium supplementation might be of therapeutic
value in preventing the onset and progression of cataract60.
xxii

Oxidative stress is another important contributor to the pathogenesis of cataract. It has
been shown in many studies that nitric oxide (NO) could be a risk factor in cataract
formation61. NO production via inducible nitric oxide synthase (iNOS) causes an
oxidative stress response in the lens62. Mg2+ has been shown to prevent the increase of
NO in the lens which provides protection by inhibiting the nitrosylation of gap
junctional proteins and maintaining membrane permeability63. It is also known to
block iNOS expression and reduce the oxidative stress response. A cytological
experiment found that the expression of iNOS was 6 times higher in the lens epithelial
cells cultured in the magnesium-deficient medium compared to those cultured in the
magnesium-supplemented medium. In addition, Mg2+ was shown to regulate Ca2+
ATPase thus modulating the concentration of Ca2+ in the lens.

Both magnesium deficiency and excessive NO production have been shown to
decrease ATP levels58. The reduction in ATP levels affects the membrane-associated
Ca2+ ATPase and Na+/K+ ATPase, causing ionic imbalance in the lens. Interestingly,
the decreased ATP levels in turn may have inhibitory effects on the expression of
iNOS64. Therefore, it has been speculated that magnesium deficiency may cause an
acceleration of the progression of lens opacification (Figure 1).
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Figure 1. Magnesium deficiency contributes to the pathogenesis of cataract
development.

Glaucomatous neuroprotection
Elevated intraocular pressure (IOP) is not the sole risk factor for chronic
glaucomatous neuropathy. In fact, the search for putative non-IOP dependent factors
continues to be of significant interest. Vasomotor dysfunction has also been suggested
to contribute to optic neuropathy, by mediating abnormal hemodynamics and
oxidative stress65. In an epidemiological study, Bonomi et al. reported that reduced
diastolic perfusion pressure could be an important risk factor for primary open-angle
glaucoma66. Leske et al. reported an association between cardiovascular disease and
glaucoma which suggested a vascular role in glaucomatous progression67. It has been
well-established that Mg2+ can function as a physiological Ca2+ channel blocker which,
xxiv

in turn, prevents ischemia and provides protection to the optic nerve. A large number
of studies concerning ocular blood flow and oxidative stress response have confirmed
that Mg2+ may regulate the current strength and in activation process of Ca2+
channels68,69. Even small changes in extracellular Mg2+ levels may have significant
effects on vascular tone. Mg2+ has been shown to have a direct vasodilatory effect70-72
while magnesium deficiency has been shown to increase intracellular Ca2+levels
leading to vasoconstriction73,74. Moreover, as Mg2+ regulates Na+/ K+ ATPase,
magnesium deficiency is associated with reduced activity of Na+/ K+ ATPase and
increased intracellular Na+ and Cl- levels causing cellular swelling and apoptosis of
retinal ganglion cells (RGCs) 75.

Other studies have demonstrated an association between plasma endothelin-1 (ET-1)
levels and normal tension glaucoma (NTG). Patients with NTG in the initial stage of
visual field loss demonstrated higher plasma ET-1 levels than those with moderate
visual field damage76. An increase in extracellular Mg2+ levels inhibits ET-1, which
may induce constriction and vasospasm of the ciliary arteries, with reduced blood
supply to the optic nerve. Furthermore, ET-1 may affect the functions of axons and
astrocytes, and accelerate the apoptosis of RGCs77. It has been suggested that the
favorable effects of magnesium on the visual field may be attributed to ET-1inhibition,
suppressing vasoconstriction, improving the ocular blood flow, and preventing
glaucomatous neuropathy43.
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The ion channel of the N-methyl-D-aspartate (NMDA) receptor is calcium dependent
and subject to voltage-dependent regulation by Mg2+. Mg2+ can regulate the
glutamate-gated ion channel which, in turn, has been shown to prevent excitotoxicity
and cell apoptosis78-81. In the presence of a magnesium deficiency, the toxic effects of
glutamate on RGCs are mediated by the over stimulation of NMDA receptors, leading
to glutamate excitotoxicity and loss of RGCs in glaucoma patients. Lambuk et al.
reported that intravitreal Mg2+ could prevent retinal and optic nerve damage induced
by NMDA82. Moreover, intracellular accumulation of Ca2+associated with magnesium
deficiency has been associated with the production of free radicals83,84.

Magnesium deficiency directly increases the expression of iNOS. Lower levels of
Mg2+ have been associated with vasospasm and retinal ischemia which also enhance
the expression of iNOS85, and produce large amounts of free radicals86. Numerous
studies have shown that Mg2+ plays a neuroprotective role in inhibiting the elevated
iNOS activity of neurons in retinal ischemia87,88.

In a study by Gaspar et al., 10 glaucoma patients including 6 with primary open-angle
glaucoma (POAG) and 4 with NTG were administered magnesium 121.5mg, twice a
day for one month. Results showed that magnesium significantly increased the ocular
blood flow and improved the peripheral circulation, exerting a beneficial effect on the
visual field in glaucoma patients with vasospasm89. Aydin et al. also reported that in15
NTG patients who received 300 mg oral magnesium citrate for a month, an
xxvi

improvement in the visual field was observed, but the ocular blood flow remained
unchanged. They speculated that mechanisms other than increased ocular blood flow
may be responsible for the improvement in the visual field when given oral
magnesium therapy90. Based on these findings, it was suggested that Mg2+may play an
important role in optic neuroprotection in patients with glaucoma (Figure 2).

Figure 2. Magnesium deficiency contributes to the pathogenesis of glaucomatous
neuropathy.

The history and prospects of using magnesium materials in glaucoma drainage
surgery
Due to the unique properties of magnesium and its satisfactory bio-compatibility, the
use of the pure materials was considered as an implant for the treatment of glaucoma
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in the middle of the 20th century. In 1940, Troncoso utilized pure magnesium
implants to increase the aqueous outflow in the treatment of glaucoma91. Five years
later, Boshoff used this technique to treat a patient with neovascular glaucoma who
refused enucleation, Twelve hours after operation, the patient’s whole anterior
chamber was filled with gas and the IOP was significantly increased, resulting in
severe pain. The pressure of the gas was relieved by venting with a thin hypodermic
needle. The IOP normalized on the sixth postoperative day, but huge bubbles were
still found in the anterior chamber and the conjunctiva, which disappeared on the
tenth day. Interestingly, before the operation the cornea was opaque at an IOP of 54
mmHg, but it became absolutely clear when the anterior chamber was full of gas,
despite the elevated IOP which varied from 49 to 55 mmHg. The postoperative IOP
was controlled at 1-4 months after surgery, but elevated to 45mmHg again at the fifth
month. Gonioscopy revealed complete circumferential iridocorneal synechiae. Coarse
pigment granules were observed in the dependent part of the angle. Eventually, the
eye was removed. Pathological examination revealed a closed filter channel and
massive fibroblast proliferation around the incision92.

These experiences indicated that pure magnesium had significant adverse effects due
to the excessive corrosion when in contact with body fluids due to hydrogen gas
emission. This limited its potential therapeutic benefits when used as a pure, uncoated
material.

Since then, advancements in the area of coating technology have allowed

the synthesis of novel coated magnesium alloys with optimized compositions
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(containing aluminum, zinc, manganese, calcium, praseodymium, or neodymium)
allowing control over the corrosive properties. Coated magnesium alloys have shown
significant promise as effective biodegradable materials in vivo.

During the last 15 years, biodegradable metallic stents have been developed and
investigated as alternatives for the currently-used permanent cardiovascular stents93-95.
Traditional cardiovascular stents have significant drawbacks including irritation and
damage to the vascular endothelium, leading to stenosis and blockage 96-99. In order to
solve these problems, absorbable magnesium materials have shown success. In vitro
studies have demonstrated that magnesium cardiovascular stents can maintain the
integrity and function of endothelial cells, as well as reduce inflammation and
fibroblast proliferation. In these studies, stents could be fully absorbed within 2-4
months with few complications observed during a two years of follow-up period37,39.
Subsequently, a large number of clinical trials were conducted37,38. In 2007, a
prospective multi-center trial in patients with coronary heart disease was published in
the Lancet, which showed that biodegradable magnesium stents achieved an
immediate angiographic result similar to the result of traditional metal stents and was
safely degraded after 4 months 100.

The introduction of magnesium cardiovascular stents has led to interest in how their
use can be expanded into other areas of the body. In particular, their potential utility as
an adjunctive device in glaucoma surgery is of high interest due to recent
xxix

developments in the area of micro-invasive glaucoma procedures. The excellent
biocompatibility and bio-degradability have the potential to allow magnesium alloy
devices to effectively decrease postoperative irritation, reduce scar formation,
improve the success rate of glaucoma surgery, and minimize the long-term effects of
permanent implants which tend to produce local complications related to tissue
compression. The liberation of Mg2+ cations during the natural degradation process
has many potential beneficial effects on the cornea, lens, retina, choroid, and optic
nerve.

In conclusion, bio-absorbable coated magnesium alloys may be a very promising
candidate for the development of a new generation of glaucoma drainage devices.

xxx
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Chapter 1
Introduction
1.1 Glaucoma
The glaucoma is a group of diseases that have in common a characteristic optic
neuropathy with associated visual field loss for which elevated intraocular pressure
(IOP) is one of the primary risk factors.

Most patients with early glaucoma are asymptomatic. The great majority of patients
lack pain, ocular inflammation, or halos.

Significant peripheral vision can be lost

before the patient notices visual disability. If glaucoma is detected early and treated
medically or surgically, blindness can be prevented.

1.1.1 Epidemiology of glaucoma
The World Health Organization ranks glaucoma as the second most common cause of
blindness, and as the leading cause of irreversible blindness worldwide101,102. Since
2010 there are about 60.5 million patients who suffered from primary open angle
glaucoma (POAG) and primary angle-closure glaucoma (PACG) all over the world.
The amount will become 79.6 million considerably, and it has been estimated that
over 5.9 million people worldwide will be bilaterally blind with open-angle glaucoma
by 2020103. Two main types of glaucoma can be classified according to etiology:
primary angle closure glaucoma and primary open-angle glaucoma. The highest
prevalence of open-angle glaucoma occurs in Africans, and the highest prevalence of
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angle-closure glaucoma occurs in the Inuit.

1.1.2 Aqueous Humor and Outflow
Elevated IOP is a well-known causative risk factor for both the development and
progression of glaucoma. Within the eye is a mechanism for the continuous
production and drainage of fluid. This fluid is called aqueous humor (AH). Intraocular
pressure is regulated by aqueous humor production in the ciliary body and drainage
from the eye occurs by way of the trabecular meshwork (TM) and uveoscleral
pathways.

Aqueous humour is secreted into the posterior chamber by the ciliary body,
specifically the non-pigmented epithelium of the ciliary body. It flows from the ciliary
processes into the posterior chamber, bounded posteriorly by the lens and the zonules
of Zinn, and anteriorly by the iris, to escape through the pupil into the anterior
chamber, and then to drain out of the eye via the trabecular meshwork. From here, it
drains into Schlemm's canal by one of two ways: directly, via aqueous vein to the
episcleral vein, or indirectly, through collector channels to the episcleral vein by
intrascleral plexus into the veins of the orbit and eventually general blood circulation.
Because of some resistance to the flow of aqueous through the trabeculum and
Schlemm’s canal, presuure is created in the eye.
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Figure 1.1.2 The trabecular meshwork outflow pathways.

1.1.3 Pathogenesis
Although the pathogenesis of glaucoma is not fully understood, the level of
intraocular pressure is related to retinal ganglion cell death. Intraocular pressure can
cause mechanical stress and strain on the posterior structures of the eye, notably the
lamina cribrosa and adjacent tissues. In addition, elevated intraocular pressure is not
the only risk factor for chronic glaucomatous neuropathy, In fact, the search for
putative non-IOP dependent factors continues to be of significant interest. Vasomotor
dysfunction has also been suggested to contribute to optic neuropathy, by mediating
abnormal hemodynamics and oxidative stress65.
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1.2 Glaucoma treatment options
Slowing disease progression and preservation of quality of life are the main goals for
glaucoma treatment. Current management guidelines from the American Academy of
Ophthalmology Preferred Practice Patterns recommend lowering the intraocular
pressure toward a target level, which is a value or range of values at whichthe rate of
disease progression will be slowed sufficiently to avoid functional impairment from
the disease104. The target intraocular pressure should be achieved with the fewest
medications and/or surgeries, and with a minimum of adverse effects. When glaucoma
is no longer controlled by maximally tolerated medical therapy or laser
trabeculoplasty, incisional ab externo filtering surgery has been the traditional next
step in the therapeutic management.

1.2.1 Filtration surgery
Filtration surgery still plays a mainstream role in the treatment of glaucoma despite
the fact its development dates back to the 19th century. Trabeculectomy (TRAB) is
still the most popular surgical intervention in patients who aﬀected by primary
glaucoma, and is the most commonly performed incisional surgical procedure to
lower intraocular pressure. The trabeculectomy was introduced almost 50 years ago
with very few modifications since that time.

Trabeculectomy is generally

recommended for patients with glaucoma that continues to progress despite use of
medications and/or laser treatments. It consists of excision of a small portion of the
trabecular meshwork tissue to provide a drainage route for aqueous humor from
within the eye to underneath the conjunctiva where it is absorbed. However, the
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trabeculectomy can contribute to a number of adverse effects, such as: scaring,
bleeding, infection, malignant glaucoma. Therefore, a new class of glaucoma
procedures, termed microinvasive glaucoma surgery, has emerged, which aims to fill
the gap between conservative medical management and more invasive surgery.

1.2.2 Glaucoma drainage devices
Although the procedure itself has not changed much in the last 50 years, chemical
agents that modulate the fibroblastic response to the surgery have been more recently
introduced. These agents, known as 5-fluorouracil and mitomycin C have effects at
the cellular level in blunting the would healing response.

In addition,

trabeculectomy is not the only choice of ab externo glaucoma surgery . These
procedures have been augmented, traditionally in more advanced cases, with macroglaucoma drainage devices and implantations. Glaucoma drainage devices are
designed to divert aqueous humor from the anterior chamber to an external reservoir,
where a fibrous capsule forms about 4-6 weeks after surgery and regulates flow.
Lowering IOP can be achieved by increasing aqueous humour drainage through this
artiﬁcial route. These devices have shown success in controlling intraocular pressure
(IOP) in eyes with previously failed trabeculectomy and in eyes with insufficient
conjunctiva because of scarring from prior surgical procedures or injuries. They also
have demonstrated success in complicated glaucomas, such as uveitic glaucoma,
neovascular glaucoma, and pediatric and developmental glaucomas, among others.
Therefore, glaucoma drainage devices are being used increasingly in glaucoma
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surgery. Currently, the glaucoma drainage devices are available in different materials.
These “macro” ab externo adjunctive devices provided a basis for the emergence
ofthe first generation of micro-incisional devices. The latter have been made of
various materials with one of the first being titanium.

1.3 Fibrosis
1.3.1 Anti-fibrotic agents
In general, filtering procedures such as trabeculectomy or placement of
subconjunctival drainage implants, aim at allowing aqueous humor to leave the
anterior chamber through a novel transscleral route towards the subconjunctival space.
Scarring is a major cause of increased intraocular pressures and surgical failure. In
order to prevent bleb scarring and obstruction of the fistula, the inhibition of cellular
proliferation and inﬂammation is both necessary and desirable after surgery for
glaucoma. Currently, various substances have been used for the modulation of wound
healing in filtering glaucoma surgery. In ﬁltering glaucoma surgery, the most
frequently used anti-fibrotic agents are mitomycinC (MMC), and 5-ﬂuorouracil
(5-FU). These anti-fibrotic agents improve the success rate for long-term intraocular
pressure (IOP) control and reduce the risk of bleb failure105,106. but their use is
associated with an increased complication rate including thin-walled blebs107,
hypotony108, wound leakage109 and infection110. Until now, no satisfactory methods
have been developed to resolve this issue.
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Figure 1.3.1 Clinical presentation of filtering blebs.
(A) Unscarred diffuse filtering bleb 12 months following trabeculectomy. (B) Scarring filtering bleb
with beginning encapsulation (arrows) and enhanced vascularity, 6 weeks following trabeculectomy. G.
Schlunck et al. / Experimental Eye Research 142 (2016) 76-82.

1.3.2 Permanent foreign body under tenos’s capsule stimulates fibrosis
Currently, permanent and inert metals like Titanium alloy, Polypropylene, and
Silicone are the most common materials used in adjunctive glaucoma surgical
devices. . However, it has been found that these materials can be associated with
long-term complications. One reason is that the presence of the permanent foreign
body induces inflammation stimulation under the tenon’s capsule. The initial process
of inflammatory is characterized by the increasing of monocytes and lymphocytes
with the early proliferation of connective tenon’s capsule tissue111. Thisis a main risk
factor cause fibroblast proliferation112-114 and fibrosis115,116.

Inflammatory responses of organisms against foreign body are a natural defense
process, which, in turn, is one of the greatest challenges in the development of
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permanent implantable devices117,118. The foreign body may be associated with
subconjunctival inflammation due to toxic and allergic responses. The inflammatory
phase is characterized by the activation of the innate immune system and the release
of inflammatory cytokines. Chronic inflammation is an established risk factor for
fibrosis due to the release of mediators such as interleukin-1（IL-1） and tumor
necrosis factor-alpha （TNF-α）which lead to increased tissue levels of TGF-β.
Chronic inflammatory reactions associated with the foreign body can accelerate
wound scarring, resulting in failure of the glaucoma surgery. It is for these reasons
that higher surgical success rates may occur if the inhibitory substances remain in
intimate contact with the tissue whose proliferation should be prevented, while
supporting the well-being of the tissues whose integrity is necessary to prevent
complications and promote healthy function.

Ideally, the implantable material would

do its job in the acute phases of wound healing and then auto-degrade to limit the
potential for chronic responses to a foreign body.

Figure 1.3.2 Conjunctival scarring following filtering glaucoma surgery.
Fibroblasts (orange) proliferate and differentiate into myofibroblasts (red). Drivers of fibrosis: (1)
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sutures, (2) blood, vessel-derived cells, cytokines and growth factors, (3) aqueous humor-derived
growth factors, (4) shear force stimulation by interstitial fluid flow, (5) signaling molecules released
from ECM storage sites, (6) myofibroblast transdifferentiation leading to matrix deposition and tissue
compaction. G. Schlunck et al. / Experimental Eye Research 142 (2016) 76-82

1.4 Magnesium
1.4.1 The important roles of Mg2+
Magnesium is an essential trace element for human life, and is one of the most
important regulatory cations involved in several biological processes. Magnesium is
the most common divalent cation in the intracellular fluid, and plays an important role
in regulating vascular functions and energy metabolism, as well as maintaining water
and electrolyte balance. Mg2+ is important for maintaining the structural and
functional integrity of several vital ocular tissues such as the cornea; lens and retina 119.
Magnesium deficiency may contribute to the pathogenesis of many eye disorders,
including, cataract, conjunctival diseases, corneal diseases, choroidal diseases, and
retinal diseases. Magnesium is a nature’s calcium blocker120, increase blood flow to
tissues through endothelin-1 and endothelial nitric oxide pathways121. As well as,
magnesium has been shown neuroprotective role to glaucoma patients122,123 that
prevent oxidative stress and apoptosis124.

1.4.2 Magnesium alloys
Magnesium alloy has a variety of advantageous characteristics which include:
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biodegradable, non-toxic, high strength, light weight, and high biological
compatibility125. Due to the unique properties and satisfactory biocompatibility the
application of magnesium alloy as a bio-absorbable material in clinical practice can be
traced back to the early 1900s for treatment of bone fracture patients, which
demonstrated it was a non-toxic biomaterial21-23. Magnesium alloy also has been
considered as a potentially appropriate biomaterial for glaucoma drainage devices.
Various studies have found that magnesium alloys are biologically safe and have
demonstrated positive biological reactions in ocular tissue126. In comparison with
polymers, the degradation products of the alloys which includes magnesium ions are
needed in the human body for physiological functions, with consumption lying in the
range 250–500mg day. About 20g of Mg is always present in the average 70kg human
body127.

1.4.3 Coating techniques improve corrosive property
Magnesium as a pure metal has poor corrosion resistance, which has been
obstacle to their application as a human implantable device.

a major

If corrosion is rapid and

not homogenous, it limits its potential in vivo applications. Another issue is the
formation of hydrogen gas during corrosion: if evolution of the gas is too rapid it
cannot be absorbed and a balloon effect takes place. Fortunately, in recent years, the
most attention in the magnesium alloy field has been the study of coatings or surface
modification to slow the degradation rates of various Mg alloys. This has caused a
renewed interest in the use of magnesium as a surgical adjunctive device. There are a
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large number of possible coating technologies for Mg biomaterials, including
anodisation, metal–metal coatings, plasma spray, chemical vapour deposition, pulsed
laser deposition, ion beam assisted deposition, solution coatings, calcium phosphate
(CaP) deposition achieved by various means and the well known methods of
electrodeposition and conversion coating. The CaP coatings have garnered the
majority of attention due to their intrinsic biocompatibility128-130, due to the formation
is similar to the mineral phase of bone, including hydroxyapatite (HA), dicalcium
phosphate dehydrate (DCPD) and dicalcium phosphate dehydrate +Stearic acid
(DCPD+SA).

Nowadays, the advancement techniques have fabricated a new generation of
magnesium alloys, especially the development of coating technique which effectively
reduced the production of gas and rapid corrosion in the body. The coated magnesium
alloys have been used to develop novel cardiovascular stents resulting in a number of
clinic trials37-39.

It is for these reasons that we were interested in exploring the

feasibility of coated magnesium devices as a potential surgical adjunct to glaucoma
surgery.

1.5 Hypothesis and Objectives
The preliminary data showed that coated magnesium alloy may reduce metabolic
activity and potentially inhibit human tenon’s capsule fibroblasts（HTCFs）cells
growth and proliferation. The results indicated that different coated magnesium alloys
had different inhibitory ability on HTCFs proliferation, and this effect may be
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associated with the capacity of blocking cell cycle.

1.5.1 Hypothesis
Bio-degradable coated magnesium alloys will inhibit cellular proliferation and reduce
myofibroblast activity in a primary culture of human Tenon’s capsule fibroblasts.

1.5.2 Objectives
The purpose of this study was to evaluate the biocompatibility and anti-proliferative
potential of different coated magnesium alloys on the activity of human Tenon’s
capsule fibroblasts in primary cell culture.
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Chapter 2
Primary cell culture and sample preparations
2.1 Materials and methods
2.1.1 Primary HTCFs culture
The tenon’s capsule samples were obtained from 32 glaucoma patients without a past
history of ocular surgery. The study has been approved by the Research Ethics
Committee of St. Joseph’s Hospital, Western University, London, Canada. All the
patients provided informed consent, and the study was conducted in accordance with
the Declaration of Helsinki. The capsule samples were excised during the surgery, and
cultured in a 60 mm dish. The culture medium, consisting of Dulbecco’s modified
Eagle’s medium (DMEM, Gbico, USA) supplemented with 10% fetal bovine serum
(FBS, USA) and 1% penicilin/streptomycin (Gbico, USA), was changed every 2-3
days and the cells were allowed to reach 80% confluence. Subsequently, the cells
were disaggregated with 0.25% trypsin and 0.02% EDTA at 37oC for 5 min. And then,
the HTCFs cells were transferred to 25 cm2 flasks (BD Falcon, BD Biosciences,
Broendby, Denmark), which were placed at 37oC in 5% CO2 incubator for subculture.
The cells were seeded in a 24-well plate when they reached 80% confluence.

2.1.2 Assessment of morphology
The cells were analyzed 2 days after seeding. Cell counting was performed by
fluorescence microscopy (Axio Observer. Z1; Carl Zeiss, Germany) using Heochst
dye (Molecular Probes, Carlsbad, CA, USA) to visualize the nuclei. After 10 minutes
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of incubation with the fluorescent dye, the cells were fixed with 4% buffered
formaldehyde in phosphate buffered saline (PBS) for 10 minutes, and then
permeabilized with 0.1% Triton-X 100 in PBS for 5 minutes. Thereafter, the samples
were rinsed with PBS, stained with a 1:100 dilution of monoclonal mouse
anti-vimentin and 1:500 monoclonal rabbit anti-keratin, and then left overnight at 9oC.
After a PBS rinse, the samples were incubated in a 1:625 dilution of anti-mouse Alexa
Fluor 488-conjugated goat anti-mouse IgG for 1 hour at room temperature. For double
labeling, the samples were also incubated in a 1:500 dilution of Alexa Fluor
568-conjugated donkey anti-rabbit IgG for 1 hour at room temperature. Finally, the
samples were rinsed twice with PBS and kept in PBS at 4oC until the observation
time.Image sampling, cellular morphology assessment and cell counting were
performed using custom-written routines for the AxioVision rel.4.7 software (Carl
Zeiss).

2.1.3 Fabrication of differently coated magnesium alloys
Magnesium alloys with a purity of 99.99% were obtained from the National
Engineering Research Centre for Magnesium Alloys, Chongqing University, China.
The pure magnesium was cut into disks with 14.5 mm in diameter and 1 mm in
thickness after pretreatment at 550oC for 24 hours of annealing. The surface of the
disks was polished using 320-800# abrasive paper. All of the disks were ultrasonically
cleaned in acetone, air dried and weighed. Thereafter, the magnesium disks were
coated with hydroxyapatite (HA, Figure 2.1.3.A), dicalcium phosphate dihydrate
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(CaHPO4·2H2O, DCPD, Figure 2.1.3.B), and DCPD + stearic acid (DCPD + SA,
Figure 2.1.3.C), respectively. The HA coating was composed of 0.25 mol/L
ethylenediaminetetracetic acid calcium disodium salt hydrate (Ca-EDTA) and 0.25
mol/L potassium dihydrogenphosphate (KH2PO4), and the thickness of coating was
2um. The DCPD coating was composed of 3.1% sodium hydrogen phosphate
(Na2HPO4) and 5.3% calcium nitrate (Ca(NO3)2). The HA and DCPD coatings formed
with chemical bond of calcium phosphate and magnesium matrix. The thickness of
DCPD coating was 3um. The DCPD + SA coating was treated based on the
DCPD-coated magnesium disks with the addition of stearic acid. The combination of
SA depends on hydrogen bond and physisorption. The thickness of DCPD+SA
coating was 4um. Finally, all of the coated magnesium disks were ultrasonically
cleaned.

(a)
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(b)

(c)

Figure 2.1.3 Scanning electron microscope (SEM) images of different magnesium coatings.
(A) SEM morphology of HA; (B) SEM morphology of DCPD; (C) SEM morphology of DCPD +
SA.

2.1.4 Magnesium sample preparation
The coated magnesium samples were immersed in 70% ethanol for 10 minutes, and
rinsed twice with distilled water, and then dried under UV light. The samples were
introduced into a separate 24-well plate (BD Falcon, BD Biosciences, Broendby,
Denmark), with 5 x 104 primary HTCF cells per well (Invitrogen Countess™). The
glass and titanium disks were used as controls (Figure 2.1.4).
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During the experiments, if a coated magnesium disk emitted hydrogen gas, the gas
would elevate the disk. We defined this phenomenon as corrosion, recorded it and did
not use such disks for our experiments.

Figue.2.1.4 Different sample groups for experiments.

2.1.5 Statistical analysis
The corrosion rate of differently coated magnesium alloys were compared using
chi-square test. The corrosion susceptibility of different coatings from day 2 to day 7
was compared using two-way analysis of variance (ANOVA). Statistical significance
was accepted at P < 0.05. All analyses were performed using SPSS 24.0 software.

2.2 Results
2.2.1 Cell morphological observation and identification of HTCFs by
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immunofluorescence staining.
The cells migrated out from the tissue after 7-10 days of adherent culture.
Microscopically, the cells exhibited a fusiform appearance with clear outline, and the
cellular plasma was abundant, bright, and uniform-sized. The cells were arranged in
fasciculus or swirling patterns. No differences were observed between the recovered
cells and those before cryopreservation in terms of morphology and growth
characteristics. The results revealed that the cells were positive for the expression of
vimentin, and the specific fluorescence could be observed within the cytoplasm
(Figure 2.2.1). The cells were negative for the expression of keratin. This supported
their identity as fibroblasts.

A

１９

B

C
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D

Figure 2.2.1 Immunostaining and characterization of primary human Tenon’s capsule
cultures. Cells were stained for nuclei (blue), vimentin (green), and keratin (red) under 40x
magnification. Image A shows a complete image while B, C, and D show isolated images for
nuclei, vimentin, and keratin stains respectively. Images displayed are representative of all images
of samples taken.

2.2.2 Corrosion of different coated magnesium alloys
A total of 453 coated magnesium alloy disks were used in our experiments: 399 for
assessment of metabolic activity, cytotoxicity, and cellular proliferation rates, and 54
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for western blot analysis (Table 2.2.2). The phenomenon of corrosion was observed in
67 disks, accounting for 14.8%. The coating of DCPD and DCPD + SA had the same
corrosion proportion (both 15.9%), while the HA coating had the lowest corrosion
proportion (12.6%). The difference, however, was not statistically significant
(chi-square test, χ2 = 0.876, P = 0.645).

Table 2.2.2 Corrosion rate of different coated magnesium alloys (events).

DCPD

DCPD+SA

HA

Total

Corrosion

24

24

19

67

No corrosion

127

127

132

386

Total

151

151

151

453

Proportion

15.9%

15.9%

12.6%

14.8%

The difference was not statistically significant (chi-square test, χ2 = 0.876, P = 0.645).

2.2.3 The corrosion susceptibility of different coatings from day 2 to day
7
A total of 324 samples were used for assessment of metabolic activity and
cytotoxicity from day 2 to day 7. As shown in Table 2.2.3, corrosion of the HA
coating was more frequently found during the last three days (8/10), while corrosion
of the DCPD coating was more commonly seen during the first three days (6/9). The
two-way ANOVA analysis revealed that the corrosion susceptibility of different
coatings was not statistically different (Pcoating=0.729, Pday=0.903).
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Table 2.2.3 The corrosion susceptibility of different coatings on different days (events/disks).

DCPD

DCPD+SA

HA

Day 2

2/18

1/18

0/18

Day 3

3/18

1/18

1/18

Day 4

1/18

1/18

1/18

Day 5

0/18

2/18

3/18

Day 6

1/18

1/18

3/18

Day7

2/18

1/18

2/18

The difference was not statistically significant (two-way ANOVA, PCoating=0.729, PDay=0.903).

2.3 Discussion
Coatings increased the corrosion resistance of magnesium alloys
The total corrosion rate was 14.8%, and the HA coating showed a relatively more
stable property compared with DCPD and DCPD + SA.

Mg alloys have unique properties, providing the mechanical benefits of a metal
combined with the degradable and biological advantages of biomaterials 131. However,
in spite of significant recent research, corrosion is a major challenge to successful
implementation of Mg-based materials in the body. In addition, the wear resistance of
Mg and Mg alloys is not very high. Therefore, a broad range of coating systems have
been developed to overcome these weaknesses for numerous applications 132,133.
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Recently, calcium phosphate-based coatings have attracted special interests for
biomedical application as bone substitutes and orthopaedic materials
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, including

DCPD, DCPD + SA, and HA. Particularly, the formation of a HA layer is similar to
the mineral phase of bone

135-137，

and more smoothly than other two coatings. In our

experiments, the HA coating was more stable than DCPD or DCPD + SA.
Interestingly, in the MTT and LDH assays, where disks were immersed in the culture
medium for 7 days, most of the corrosion events of the HA-coated magnesium alloys
occurred during the last three days, accounting for 80%. Therefore, we conclude that
the HA coating has better corrosion resistance at the beginning of the cellular
logarithmic phase.
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Chapter 3
Corrosive properties of coated magnesium alloys in simulated
aqueous humor
3.1 Background
Due to their excellent bio-compatibility, magnesium alloys are being considered as
promising implant materials. However, the poor corrosion resistance becomes a major
obstacle to their widespread applications. Currently, the focus of bio-magnesium
studies is on coatings or surface modification to slow the degradation rates of Mg
alloys. If coated magnesium alloys are going to be used a biomaterial candidate for
glaucoma drainage device, not only gradual degradation is needed to control the
overall corrosion process, but also pH maintenance and control of ions released into
the anterior chamber are also required to maintain a non-toxic concentration of each
ions. These conditions very rapidly alter as a result of the corrosion process, with
rapid changes in pH levels and metal ion concentrations, as well as presence of
soluble corrosion products and hydrogen gas evolution. Thus, we need a complicated
solution that considers the corrosion resistance, metal ion concentrations, pH and
mechanical performance of coated magnesium alloy implants when immersed in the
aqueous humor. It is essential to fully understand the long term corrosion engineering
and potential biological interactions. Thus we invited our collaborators (National
Engineering Research Center for Magnesium Alloys, Chongqing University, China)
using balanced salt solution to test the variation of pH, sample’s weight, and ion
concentrations.
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3.2 Materials and methods
3.2.1 Corrosion resistance test
The corrosion resistance, ion release, sample weight change, and pH change were
investigated by immersion of coated and uncoated magnesium alloy samples in
balanced salt solution (BSS, Alcon, USA). The BSS components are shown in Table
3.2.1.
Four prepared samples were placed on a specially made PVC plastic stent and soaked
in a 150ml containing balanced salt solution (BSS), and each sample was weighed
before test. Each sample set 4 groups, each group of a specimen in a ground glass
stoppered flask. And then remove flasks to a 37℃ 5% CO2 incubator(Shanghai
Shengke 101) .

3.2.1.1 The SEM morphologies
The SEM morphologies were observed at 5 and 9d. The coated sample was covered
with specific conductive liquid to allow it to conduct electricity. The pure maganism
sample can be directly placed in the electron microscope.

3.2.1.2 The pH test
The pHs of three groups in each sample were measured at 1, 2, 5, 9, and 15d. The
electrode was rinsed by BSS before test. The instrument of pH test was Shanghai Lida
phs-3c.
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3.2.1.3 Variation of weight
3 discs of each sample were taken out respectively at 2, 5, 9, 15 and 21d. The discs
were rinsed by deionized water and 100% ethanol, and then slowly dried the discs
with cold wind. After weighed on an electronic scale, the discs continued to immerse
in BSS.

3.2.1.4 Variation of ion concentrations
2ml different soaking solutions were extracted at 1, 5, and 9d, respectively, diluted
two times, detection of magnesium, calcium, phosphorus content in solution, and
compared with BSS solution. The result of these three ions content was removed the
content of ions in the blank solution. The instrument used is inductively coupled
plasma emission spectrometry (ICP-OES)

Table 3.2.1 Components of aqueous humor and simulated aqueous humor.
Aqueous humor

Balanced salt solution (Alcon)

Na+ (mmol/L)

163

156

K+ (mmol/L)

2.3-3.9

10.1

Ca2+ (mmol/L)

1.8

3.3

Mg2+ (mmol/L)

1.1

1.5

Cl- (mmol/L)

132

129

pH

7.38

7.4

304

305

Osmotic
(mmHg)

pressure

3.3 Results
3.3.1 Microstructure of different coatings
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The SEM morphologies for different coatings are shown in Figure 3.3.1. After
immersion for 9 days, the coating of DCPD and DCPD + SA was dissolved and
flaked, with cracked surface. The HA coating was exfoliated from the matrix on day 5,
but without any obvious changes on the surface of non-exfoliated areas.

A

B

C

D
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E

F

Figure 3.3.1: SEM images of coated magnesium samples after immersion under different
magnifications.

Image A and B shows the DCPD coated sample at 100x and1000x magnification.

Image C and D shows the DCPD+SA coated sample at 100x and 500x magnification. Image E and F
shows the HA coated sample at 500x and 2000x magnification. Graphs from National Engineering
Research Center for Magnesium Alloys, Chongqing University, China

3.3.2 pH variations of BSS
As shown in Figure 3.3.2, the pH levels of all samples rapidly increased during the
first two days. The pure magnesium group had higher pH levels compared with other
groups, but after day 5, the pH levels of the pure magnesium group slightly declined.
The pH levels of all coating groups gradually increased after day 2. The pH levels of
the HA coating group was constantly higher than those of the DCPD and DCPD + SA
groups.
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Day
Figure 3.3.2 Variation of BSS pH of coated and uncoated samples over time.
The pHs of three groups in each sample were measured at 1, 2, 5, 9, and 15 days. The electrode was
rinsed by BSS before each test. Graphs from National Engineering Research Center for
Magnesium Alloys, Chongqing University, China

3.3.3 Sample weight changes in BSS
The changes of sample weight during the immersion test are shown in Figure 3.3.3.
The sample weight was slightly reduced in the pure magnesium group and the HA
coating group during the first 5 days, but gradually increased after day 5. The sample
weight of the DCPD and DCPD + SA groups was dramatically reduced during the
first 2 days, but gradually increased after day 2 in the DCPC + SA group. In the
DCPC group, weight loss became slower from day 2 to day 5, but the sample weight
began to increase after day 5.
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Figure 3.3.3 Weight changes of coated and uncoated samples over time.
Discs were taken out at 2, 5, 9, 15 and 21 days. The discs were rinsed by deionized water, 100%
ethanol, air-dried and then weighed on an electronic scale. Graphs from National Engineering
Research Center for Magnesium Alloys, Chongqing University, China

3.3.4 Changes of ion concentrations during immersion test.
As shown in Figure 3.3.4.a, the magnesium concentration of all groups gradually
increased from day 1 to day 9. The magnesium concentration in the pure magnesium
group was obviously higher than that of other groups.

The calcium concentration of the DCPD and DCPD + SA groups was much higher
than that of the HA group (Figure 3.3.4.b). The calcium concentration of all the
coating groups rapidly increased on day 1, and then declined afterwards. The calcium
concentration of the DCPD + SA group rocketed at the beginning, but rapidly dropped
after day 1 and became lower than that of the DCPD group after day 5.
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As for the changes of the phosphorus concentration (Figure 3.3.4.c), the DCPD and
DCPD + SA groups showed a similar trend with that of calcium, i.e. rapid increase on
day 1, and then gradual reduction afterwards. The DCPD group had a higher
phosphorus concentration than that of the DCPD + SA group. Interestingly, the
phosphorus concentration was not detectable in the HA group.

(a)

(b)
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(c)

Figure 3.3.4 Ion concentration changes during immersion test.
(a), (b) and (c) illustrate the changes of magnesium, calcium and phosphorus concentrations
during immersion test, respectively. 2ml different soaking solutions were extracted at 1, 5, and 9d,
respectively, diluted two times, detection of magnesium, calcium, phosphorus content in solution.
Graphs from National Engineering Research Center for Magnesium Alloys, Chongqing
University, China

3.4 Discussion
3.4.1 Effect of coating on corrosion process
BSS is an intraocular irrigating solution commonly used in ophthalmic surgeries to
perfuse and support the anterior chamber to prevent its collapse during operation. Its
properties, including pH value, ion concentrations and osmotic pressure, are generally
similar to those of human aqueous humor. Thus, BSS was applied in the immersion
test as simulated aqueous humor.
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The pH level of BSS and aqueous humor is 7.4, which may corrode magnesium alloy,
while the presence of chloride (Cl-) ions would aggravate the corrosion leading to
dissolution of magnesium

138,139

. The dissolution of magnesium consumes the

hydrogen (H+) ions in the solution, resulting in a continuous rise in the pH of the
solution

140

. During the immersion test, the pure magnesium group had higher pH

levels than other groups, indicating that coating could prevent dissolution of the
matrix and protect against corrosion, thus delaying changes in the pH level.

The samples is stable in the dry air is long-term and stable. In vitro experiment, by
immersion in BSS for 21 days, the DCPD and DCPD+SA coated samples lost about 1%
weight loss, HA and pure magnesium did not test to weightlessness. Weight loss of
samples is caused by dissolution of coating and matrix. The surfaces of coatings have
some small pores that causing the solution permeate into the matrix. Although the
corrosion of coating and matrix almost occur at same time，but in the early stage,
corrosion medium is slow and difficult to penetrate the coating. According to the pure
magnesium disks almost did not lose any weight during the test, and thus it could be
concluded that dissolution of the coating was the major contributor to weight loss.
Similarly, the weight of the HA disks remained almost the same throughout the test,
indicating that the coating of HA had better ability to protect against dissolution.
Compared with the DCPD and DCPD + SA coated samples, the HA coated samples
had lower weight loss rate because of the protective effect on the matrix. Additionally,
the oxide layer of the original metal surface grows inwards and outwards at the same

３４

time, and thus the weight change of samples consists of two parts: dissolution causing
weight loss and deposition of magnesium hydroxide (Mg(OH)2) causing weight gain
141

. During the later stage of this test, magnesium hydroxide deposition might exceed

dissolution, leading to increases in the sample weight．This explains why the weight
of each group gradually increased after rapid decline.

According to these results, our collaborators estimated that the pure magnesium in
BSS solution can maintain the stability for more than 1 month and the coated
magnesium alloys can maintain the stable state for longer periods. But vitro
experiments had big difference compare to vivo experiments, because there is no
bioactivity in vitro experiment. Therefore，the purpose of immersion corrosion test is
screening for a promising coating for future research.

3.4.2 Ion release of different samples during immersion test.
Compared with the DCPD and DCPD + SA coated samples, the HA coated samples
released fewer ions contained in the coating. This finding demonstrated that the
coating of HA could prevent dissolution and corrosion of magnesium alloys in an
effective and stable manner. Interestingly, DCPD is a precursor for the synthesis of
HA 141,142; it can be dissolved in physiological environment and release calcium and
phosphorus which form of HA with precipitation

143

. This is why more calcium and

phosphorus ions were released in the DCPD and DCPD + SA groups. However, the
dissolution rate of the DCPD and DCPD + SA coating was higher than inducing the
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formation of HA crystals.

3.4.3 SEM morphologies of different coatings after immersion test
According to the SEM photographs, the coating of DCPD and DCPD + SA was
dissolved and flaked, with cracked surface observed on day 9. Although the HA
coating was exfoliated from the matrix, no obvious changes were noted on the surface
of non-exfoliated areas. Therefore, we speculate that the main problem of the HA
coating is an increased risk of detachment from the matrix. If it can be improved to
attach more closely with the matrix, we believe that this type of coating could
effectively reduce the corrosion rate of magnesium alloys.
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Chapter 4
The effect of different coatings on metabolic activity and necrosis of
HTCFs
4.1 Background
Various kinds of metal-based tissue implants have been developed since the 20th
century. But they still have many defects that remain to be addressed. For instance,
nickel-titanium alloy implants cause potential harm to the human body 144, because of
the release of Ni+. The titanium has been widely used as a biocompatible surgical
device. Despite the wide belief that it is inert, allergic reactions and stress shielding
effects have been reported after implantation 145.

Magnesium is the second most common cation in the intracellular fluid, also the
fourth most common metallic ion in the body, mainly located in the cytoplasm. It
participates in a series of metabolic processes in the body. In order for magnesium
alloys to be developed as a tissue implantable material in the future, we not only need
to solve the key adverse effect of corrosion in the human body, but also consider the
cytotoxicity of coating and its effects on cellular metabolism. Therefore, it is very
important to investigate the biocompatibility of differently coated magnesium alloys.

In our previous experiments, differently coated magnesium alloy disks were used to
treat cells for only 24 hours, but as a potential biomaterial for future glaucoma
drainage devices, coated magnesium alloys would exist in the conjunctiva for a
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relatively longer period of time, and thus it would be necessary to investigate the
long-term effect of differently coated magnesium alloys on HTCFs.

4.2 Materials and methods
4.2.1 MTT assay
The primary HTCFs were seeded on DCPD, DCPD + SA, and HA disks in a 24-well
culture plate, 2 x 104 cells per well from Day 2 to Day 7. Glass disks were used as
controls. The assay was performed according to the manufacturer's instructions. MTT
(Sigma, USA) was added at the final concentration of about 450 ug/ml. MTT
concentrations in the stock: 5 mg/mL for 1 mL cell culture medium, and 0.5 mL was
added to each well. Cells were placed in a 37oC 5% CO2 incubator. After 3 hours, the
supernatant was aspirated from culture wells. The precipitate in each well was
resuspended by adding 0.5 mL dimethyl sulfoxide (DMSO, Sigma, USA) to solubilize
formazan crystals. Subsequently, the solution was completely mixed, and 100 uL was
removed from each well to 3 wells of a 96-well plate. Absorbances at 575 nm were
determined using a microplate reader (Molecular Devices, Sunnyvale, CA). Control
cells, which represented 100% metabolic activity, were used to normalize absorbances.
At least 6 samples per group were measured in duplicate.

4.2.2 Lactate dehydrogenase cytotoxicity(LDH) assay
The supernatant of different groups were collected from Day 2 to Day 7. Glass was
used as control. The collected supernatant was analysed using a LDH cytotoxicity kit
(Roche, USA), and the assay was performed according to the manufacturer’s
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instructions. The collected supernatant was centrifuged at 1000 x 10 min. Three 1.5
mL tubes were labeled as 1, 2 and 3. Next, 7.5 uL LDH (Sigma, USA) solution was
diluted with 992.5 uL PBS solution in tube 1, and then 100 uL solution was extracted
from tube 1 to tube 2 which contained 900 uL PBS solution. Finally, 100 uL solution
was extracted from tube 2 to tube 3 which also contained 900 uL PBS solution. To the
final row standard lanes, 200 uL of the diluted LDH solution (0.5 U/mL) was added to
2 wells of the 96-well plate. Using a multipipette with PBS, 100 uL PBS was placed
into the other wells of the standard lanes. The standards were serially diluted so that
each well had a final volume of 100 uL, and then each standard was mixed well. And
no LDH was contained in the first row. The amount of the total reaction solution was
determined and 100 uL reaction solutions was added to each well and allowed to
incubate for 10-15 min at room temperature. Optical densities of the solutions were
read at dual wavelength of 490/655 nm. Control cells, which represented 100%
cytotoxicity, were used to normalize absorbances. At least 6 samples per group were
measured in duplicate.

4.2.3 Statistical analysis
The MTT and LDH assay results were analyzed using two-way ANOVA test.
Statistical significance was accepted at P < 0.05. All analyses were performed using
SPSS 24.0 software.

4.3 Results

３９

4.3.1 Time and cellular metabolic activity curves
The MTT assay was used to determine cellular metabolic activity. In the presence of
viable cells, MTT was enzymatically reduced to the purple dye formazan. The
multiple curves represented the variation of metabolic activities of HTCFs which
were treated by different disks from day 1 to day 7 (Figure 4.3.1). The p value of
different treatments was statistically significant (ptreatment < 0.001). The metabolic
activity of the DCPD + SA group, which gradually declined from day 2 to day 7, was
significantly lower compared with other groups. The HTCFs seeded on the titanium
plates had the highest viability. The HA group showed a higher metabolic activity
during the first two days, but the viability gradually decreased and became lower than
that of the DCPD group since day 4. The P value of time was not statistically
significant (ptime = 0.195), indicating that time had no obvious influence on the
metabolic activity of HTCFs.

Figure 4.3.1 Cellular metabolic activity of different samples.
MTT results from HTCFs treated with different coated magnesium alloys. The multiple curves
represent the variation of metabolic activities of HTCFs which were treated by different disks from day
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1 to day 7. MTT was added at a final concentration of 450 ug/ml, and 0.5 mL was added to each well.
Cells were placed in a 37oC 5% CO2 incubator. After 3 hours, the supernatant was aspirated from
culture wells. The precipitate in each well was resuspended by adding 0.5 mL dimethyl sulfoxide
(DMSO, Sigma, USA) to solubilize formazan crystals. Data was analyzed using two-way ANOVA test.
The source of statistical significance was determined by applying Tukey test (SPSS 24). ***ptreatment <
0.001, ptime= 0.195; N = 6.

4.3.2 Time and cytotoxicity curves
The LDH assay was utilized to examine the cytotoxicity of coatings or necrosis of
HTCFs seeded on different disks. Liberated nicotinamide adenine dinucleotide,
formed from LDH’s conversion of lactate into pyruvate, subsequently reduced a
tetrazolium dye into formazan, which could be detected using a spectrophotometer.
The P value of treatments was statistically significant (ptreatment < 0.001). The HA
group had the lowest cytotoxicity, which was statistically different compared with
other groups. The cytotoxicity of the DCPD + SA group was higher than that of the
HA and DCPD groups, but similar to that of the titanium (p = 0.468) and glass (p =
0.976) groups. The p value of time was not statistically significant (ptime = 0.260).
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Figure 4.3.2 Time and cytotoxicity curves of different samples.
The supernatant of different groups were collected from Day 2 to Day 7. Glass was used as control.
The collected supernatant was analysed using a LDH cytotoxicity kit (Roche, USA), and the assay was
performed according to the manufacturer’s instructions. Data was analyzed using two-way ANOVA
test. The source of statistically significance was determined by applying Tukey test (SPSS 24).
***ptreatment < 0.001, ptime = 0.260; N = 6.

4.4 Discussion
4.4.1 The influence of time
A prior study reported that the logarithmic phase of HTCFs was from 48 hours to 7
days

146

. Therefore, in order to examine the relationship between the HTCFs’

metabolic activity and time, and to investigate the variation of cytotoxicity during this
period, we performed the MTT and LDH assays of treated HTCFs from day 2 to day
7. The results revealed that no statistically significant difference was observed in
metabolic activity or necrosis at different time points during the logarithmic phase
(p=0.195, p=0.260, respectively). Based on these findings, the factor of time was not a
major contributor to reduced metabolic activity and increased cytotoxicity in this in
vitro experiment. Thus, those two curves could basically describe the influence of
different treatments on HTCFs during the logarithmic phase. These results were used
to as a basis for the design of future experiments to assess cellular function, such as
BrdU, Western blotting and RT-PCR.

4.4.2 Biocompatibility of coated magnesium alloys
The purpose of this study was to evaluate the biocompatibility of coated magnesium
alloys which might be promising materials for novel drainage devices. Lorenz A et
al.147 reported that cell death on untreated pure magnesium samples occurred within 1
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day, whereas surface passivation could enable survival of a number of cells on Mg.
However, cell densities were found to be reduced on Mg samples even with prior
passivation treatments, compared with glass substrates used as a reference. Cell death
was thought to be related to the ongoing corrosion of Mg in cell culture medium,
leading to a pH increase. A recent study indicated that cell culture tests could not
provide enough volume to compensate for the high concentration of Mg2+ ions or the
alkaline pH shift in solution, and hence might not be appropriate for testing resorbable
materials
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. Although coatings could reduce Mg2+ release from pure magnesium

matrix and prevent pH increase, the coatings might influence the viability of cells and
their cytotoxicity might lead to necrosis of HTCFs.

In the MTT and LDH assays, the p value of different treatments was statistically
significant (p < 0.001). The DCPD + SA group had the lowest metabolic activity but
higher cytotoxicity than the other two coatings. The coatings of both HA and DCPD
had lower cytotoxicity than titanium and glass.

HA is attributed to the compositions of bioactive and bioresorbable ceramics or
substances close to it in composition which forms HA crystals by the reaction with the
organism at the implant-biomedium interface
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. Synthetic HA is a complete

chemical and crystalochemical analog of bone mineral. This chemical similarity with
bone accounts for their osteoconductive potential and excellent biocompatibility 135,136.
In fact, HA, as a biological material, has been used in ophthalmological clinical
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practice for a long time, such as HA orbital implants. Because of its excellent
biocompatibility, HA orbital implant exposure rarely causes rejection after
implantation

In our experiments, the HA coating also showed excellent biocompatibility which had
higher metabolic activity and the lowest cytotoxicity compared with other coatings.
Therefore, we believe that HA is a very promising type of coating for glaucoma
drainage devices.
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Chapter 5
Anti-proliferative potential of coated magnesium alloys on HTCFs
5.1 Background
Nowadays, glaucoma drainage implants have become increasingly useful in surgical
management of glaucoma, especially for refractory glaucoma
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, including

neovascular glaucoma, secondary glaucoma and remnant glaucoma. Glaucoma
drainage devices are designed to divert aqueous humor from the anterior chamber to
an external reservoir
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. However, postoperative scarring is a major risk factor

affecting surgical success rate. Moreover, glaucoma drainage device encapsulation
may result in loss of the external reservoir function, leading to IOP increase and
surgical failure.

It has been shown that inflammatory reaction is a main risk factor leading to
postoperative scarring
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. Foreign bodies inevitably induce rejection and activate

some specific proteins which will trigger a localized inflammatory response and
provide a short-term structural support. The inflammatory phase is characterized by
the activation of the innate immune system and the release of inflammatory cytokines.
At present, the commonly used materials for glaucoma drainage devices are titanium
and silicone which are not biodegradable materials. Although they have good
biological compatibility, their presence as permanent foreign body under the
conjunctiva, stimulates fibroblast proliferation and glaucoma drainage device

４５

encapsulation 153.

Magnesium alloy possesses many advantageous properties such as non-toxicity,
absorbable and high biological compatibility. However, it has been reported that the
corrosion of magnesium could increase pH levels and lead to cell death
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. In this

research we took advantage of the ability to modulate these corrosive properties by
the employing the use of coating materials. It was our goal to determine if we could
use the more controlled corrosive properties to modulate the behavior of fibroblastic
cells.

5.2 Materials and methods
5.2.1 BrdU assay
The

proliferation

of

HTCFs

was

monitored

by

5-bromo-2-deoxyuridine

(BrdU)-incorporation into cellular DNA using the Cell Proliferation BrdU assay kit
(Merck KGaA, Darmstadt, Germany) as recommended by the manufacturer. Cell
suspension in medium containing 10% FBS was placed on a 24-well culture plate
(BD Falcon, BD Biosciences, Broendby, Denmark), 0.5 mL per well at a
concentration of 0.5 x 104 cells⁄mL and was incubated for 48 hours. Cellular DNA
was labeled for 24 hours using BrdU labeling reagent. After ﬁxation, the cells were
incubated with anti-BrdU antibody for 60 min at room temperature. Then the cells
were washed, peroxidase goat antimouse IgG conjugate was added and the cells were
incubated for 30 min. After addition of substrate solution, the plate was read using a
spectrophotometer microplate reader with dual wavelength set at 450/595 nm. The
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glass group was used as control. At least 6 samples per group were measured in
duplicate.

5.2.2 Protein extraction and Western blotting analysis
Western blotting was performed on HTCFs samples derived from glaucoma patients.
After treatment, the cells were rinsed with ice-cold PBS twice, and the total cell
proteins were extracted using RIPA lysis buffer (20 mM Tris, 150 mM NaCl, 1 Mm
EDTA, 1% Triton X-100) containing phosphatase inhibitors and protease inhibitors.
Protein concentrations were determined by micro BCA protein assay (Thermo
Scientific, CA). Following the manufacturer’s instructions, 10% SDS-polyacrylamide
gel and 5% stocking gel were prepared and placed inside the electophorator
containing running buffer. And then, 6 uL marker (Invitrogen, Thermo Fisher
Scientific, CA) was loaded on the left lane, followed by 10 mg of each sample. The
gel was run at 120 V for stocking gel and at 100 V for 10% SDS-polyacrylamide gel.
Subsequently, the gel was transferred to a polyvinylidene diﬂuoride (PVDF)
membrane (Invitrogen, Thermo Fisher Scientific, CA) using a Bio-Rad gel-blotting
apparatus (Invitrogen, Thermo Fisher Scientific, CA). Membranes were blocked in 5%
milk in Tris-Buffered Saline Tween (TBST; 10 mM Tris HCl, 150 mM NaCl, 0.1%
Tween 20) for 1 hour, and probed with antibodies against α-smooth muscle actin
(α-SMA, Abcam, USA) at a dilution of 1:1000, then incubated with primary antibody
overnight at 4oC and with a peroxidase-conjugated secondary antibody for 1 hour at
room temperature. After these incubations, membranes were washed in TBST for 30
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minutes. Western blotting detection kit (WesternBright Quantum, USA) was used to
visualize for enhanced chemiluminescence (Chemi genius2, Syngene, USA) and
exposure. To ensure equal protein loading, nitrocellulose membranes were stripped
with stripping buffer (Restore, Thermo Scientific, CA) and reprobed with
anti-glyceraldehyde-3phosphate dehydrogenase (GAPDH) antibody at a dilution of
1:2000 (Santa Cruz, Biotechnology, USA). At least 6 samples per group were
measured in duplicate.

5.3 Results
5.3.1 Cell proliferation study
The BrdU cell proliferation assay was used to determine the proliferation of HTCFs.
The HTCFs seeded on the titanium disks showed a greater proliferative ability; the
cell proliferation rate of the titanium group was significantly higher than that of the
glass group (p=0.049). The proliferation rate of the DCPD + SA group was
significantly lower compared with the glass group (p=0.047); that of the DCPD group
was almost the same as the glass group; and the HA group had a slightly higher
proliferation rate than that of the DCPD group. In addition, all types of coated
magnesium alloys showed a lower proliferation rate compared with the titanium
group.
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Figure 5.3.1 Relative proliferation rate of HTCFs.
The proliferation of HTCFs was monitored by 5-bromo-2-deoxyuridine (BrdU)-incorporation into
cellular DNA using the Cell Proliferation BrdU assay kit as recommended by the manufacturer. Data
was analyzed using one-way ANOVA test (SPSS 24). *p < 0.001 compared with glass; N = 6.

5.3.2 Western blotting analysis
The protein of α-SMA is a marker of myofibrobalsts which cause fibroblast
proliferation and wound scarring
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. Normalized to GAPDH expression，the glass

group had the highest α-SMA expression. The α-SMA expression level of the titanium
group was slightly lower than that of the glass group. All types of coated magnesium
alloys had lower α-SMA expression levels than that of the titanium group or the glass
group. The DCPD group and the DCPD + SA group had similar α-SMA expressions.
The HA group had the lowest α-SMA expression level, which was significantly lower
than that of the glass group (p=0.037) and the titanium group (0.001).
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Figure 5.3.2 α-SMA protein expression normalized to GAPDH expression.
Western blotting was performed on HTCFs samples derived from glaucoma patients. The total cell
proteins were extracted using RIPA lysis buffer containing phosphatase inhibitors and protease
inhibitors. Protein concentrations were determined by micro BCA protein assay (Thermo Scientific,
CA). The test performed following the manufacturer’s instruction. Data was analyzed using one-way
ANOVA test (SPSS 24). **p=0.001; N=6.

5.4 Discussion
5.4.1 Coated magnesium alloys attenuate HTCFs proliferation
According to the BrdU cell proliferation assay, coated magnesium alloys were
associated with lower proliferation rates of HTCFs as compared with titanium. In the
BrdU assay, the same number of cells was loaded to each well at the beginning, but
due to the lower cytotoxicity and better metabolic activity of cells seeded on the
titanium disks, more cells grew and proliferated on the titanium disks after 48 hours.
The DCPD + SA coating had higher cytotoxicity and lower metabolic activity than
other coatings, and thereby a lower proliferation rate was observed in this group. Even
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if in the LDH assay the DCPD + SA group showed almost the same necrosis of
HTCFs with that of the titanium and glass groups, we still speculated that this type of
coating might cause apoptosis of HTCFs. Unfortunately, we have tried many assays to
assess apoptosis in our experiments, such as Elisa and caspase-3, but due to the
reagent reaction with coated magnesium alloy disks, the effect of each sample on the
apoptosis of HTCFs remained unclear, and further studies are needed to address this
issue.

5.4.2 HA coating inhibits α-SMA expression
HA is chemically similar to bone, and has excellent biocompatibility 135,136. Actually,
HA as a biological material has been used to fabricate orbital implants for a long time.
And HA orbital implants have been widely used in clinical practice with excellent
performance, and no obvious adverse effects have been reported
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. As the data of

α-SMA expression had been normalized to that of GAPDH, we believed that the
results of western blotting were more reliable and convincing. The expression of
α-SMA proteins is a marker of myofibroblasts, which reflects the number and
proliferation of myofibroblasts
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. It also is an important marker to estimate scar

formation or surgical prognosis. In our experiment, the α-SMA expression levels
decreased in all the coated magnesium alloy groups. Furthermore, in comparison with
glass and titanium, the HA coating significantly reduced the expression of α-SMA.
These findings indicate that HA coated magnesium alloy which has better corrosion
resistance, lower cytotoxicity and excellent biocompatibility could inhibit α-SMA
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protein expression and prevent scarring. Therefore, HA coating may be considered a
very promising biodegradable material for the next generation glaucoma drainage
devices.
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Chapter 6
Conclusion
6.1 Summary of results
As described in Chapter Two, human tenon’s capsule tissue samples were obtained
from 32 glaucoma patients. Primary cell culture and subculture were performed to
acquire

adequate

number

of

HTCFs

for

the

following

experiments.

Immunofluorescence staining performed for vimentin and keratin verified the purity
and identity of the HTCFcultures. Coated magnesium alloy and titanium samples
were fabricated and cut into disks with 14.5 mm in diameter and 1 mm in thickness,
specific for 24 well culture plate. A total of 453 coated magnesium alloy disks were
used in our experiments. The phenomenon of corrosion was observed in 67 disks,
accounting for 14.8%. The coatings of DCPD and DCPD + SA had the same
corrosion rate (both 15.9%), while the HA coating had the lowest corrosion rate
(12.6%). These differences were not statistically significant as determined by the
chi-square test. Most of the corrosion events of the HA coated samples were found
during the last three days (8/10), whereas the DCPD coated samples were more prone
to corrosion during the first four days (6/9). Based on two-way ANOVA analysis,
however, the differences were not statistically significant.

In Chapter Three, long-term changes in sample weight, pH levels, and ion
concentrations, were determined by immersion of coated magnesium alloys in BSS
solution which had similar components of human aqueous humor. The SEM
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morphologies revealed that after immersion for 9 days, the DCPD and DCPD + SA
coatings were dissolved and flaked, with cracked surface. The HA coating was
exfoliated from the matrix after 5 days, but without any obvious changes on the
surface of non-exfoliated areas. This finding indicated that the main problem of the
HA coating is an increased risk of detachment from the matrix. This coating showed
the greatest promise to effectively reduce the corrosion rate of magnesium alloys if
further development can be done to improve the attachment to the matrix. The pH
levels rapidly increased in all groups during the first two days. The pure magnesium
group had higher pH levels than other groups. The dissolution of magnesium
consumes the H+ in the solution, resulting in a continuous rise in the pH of the
solution. Thus, this result revealed that coatings could prevent pH increase because of
inhibited dissolution and corrosion of the matrix. The DCPD and DCPD + SA groups
lost much more weight than the HA and pure magnesium groups, indicating that the
coating dissolution was the major reason leading to sample weight loss during the
immersion test. Additionally, the magnesium concentration in the pure magnesium
group was obviously higher than that of the other three coated groups, which
demonstrated that coatings could reduce the release of magnesium ions from the pure
magnesium matrix. Compared with the DCPD and DCPD + SA coatings, the HA
coating released fewer calcium ions and no phosphorus ions were detected, indicating
that the HA coating was associated with a significantly lower risk of dissolution and
corrosion.
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In Chapter Four, we examined the biocompatibility of differently coated magnesium
alloys. We used MTT assay to evaluate the metabolic activity of HTCFs and LDH
assay to determine the cytotoxicity of coated magnesium alloys; the glass and
titanium disks were used as controls. Meanwhile, we utilized these in vitro
experiments to investigate the variation of metabolic activity and necrosis of HTCFs
during the logarithmic phase. The results of MTT assay showed that the P value of
treatment was statistically significant. The metabolic activity of HTCFs in the DCPD
+ SA group was the lowest, while the HTCFs seeded on the titanium disks displayed
the highest viability. The results of LDH assay also showed that the P value of
treatment was statistically significant. The HA group had the lowest cytotoxicity,
while the DCPD + SA group had higher cytotoxicity than other coatings, but
comparable to the titanium and glass groups in terms of necrosis. Notably, both of the
two assays indicated that the P value of time was not statistically significant,
indicating that time had no obvious influence on the metabolic activity and necrosis of
HTCFs from day 2 to day 7.

In Chapter Five, we attempted to utilize some of the corrosive properties of coated
magnesium alloys to evaluate their potential anti-scarring ability. The BrdU assay was
used to assess cellular proliferation, and the cells seeded on the titanium disks showed
a greater proliferative ability. Compared with the glass group, the proliferation rate of
the DCPD + SA group was significantly lower, and all types of coated magnesium
alloys showed lower proliferation rates. These results demonstrated that coated
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magnesium alloys have a better potential to inhibit cellular proliferation than titanium.
In western blotting analysis, we chose α-SMA proteins to examine the growth of
myofibrobalsts on different disks, because the expression of α-SMA is a marker of
myofibrobalsts. Normalized to GAPDH expression, the α-SMA expression was
inhibited by coated magnesium alloys. The result of ANOVA showed that the p value
was statistically significant difference. Compared with the glass and titanium groups,
the expression level of α-SMA was significantly reduced in cells seeded on the HA
disks.

6.2 Limitations of the study
Our investigation consisted of an in vitro cell culture model designed to investigate
the biocompatibility and anti-proliferative potential of differently coated magnesium
alloys as novel drainage device materials for glaucoma surgeries. As mentioned in
Chapters 2 and 3, the coated magnesium alloys tested still likely have unacceptable
corrosion rate as implant materials. In our experiments, the average corrosion
percentage was 14.8%, and even the most stable type - HA coating - still had a
corrosion proportion of 12.6%. Although the incidence of corrosion is much lower
than that of pure magnesium, it would have to be improved before this material could
be considered for in vivo surgical implantation. Actually, the coating decreased
corrosion rate of magnesium，but cannot completely prevent the occurrence of
corrosion, because the coating will gradually lose their integrity and degraded. In fact,
we do not expect that the coating could completely prevent the magnesium corrosion,
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because we expect this is a kind of biodegradable material, if the coating completely
prevent corrosion, the material becomes unbiodegradable. Based upon these
experiments, the HA coating showed the greatest promise, especially if the material
could be modified to be more closely adhere to the magnesium alloy. In the
immersion test, we selected BSS as simulated aqueous humor to investigate the
longer-term properties of coated magnesium alloys. It would have been informative to
also assess hydrogen emission, which would likely have an influence on the tissue
properties at the surgical site. Further studies are needed to examine the volume of
hydrogen emission based on the size of glaucoma drainage device.

This is an in vitro study, and, as such, it is not representative of an in vivo biological
environment. True biocompatibility profiles in animal studies would be required as a
next step towards the development of these materials as a surgical device in the
human body. Although this is a historical challenge, it is also well accepted that these
types of experiments are necessary to develop the foundation for future in vivo
experimentation, the latter that require significant resources.

In Chapter 4，we found

that magnesium alloys could reduce the metabolic activity of HTCFs and are less
likely to cause necrosis of these cells. Although attempted by ELISA, it was not
possible to assess apoptosis by this technique due to the effects of the materials on the
assay.

Future experiments that employ alternative methods for determining

apoptosis should be considered.

The proliferation rate of the DCPD + SA group

was significantly lower than other groups, but its cytotoxicity was almost the same as
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that of glass and titanium in the LDH assay. Therefore, we infer that the DCPD + SA
coating may accelerate cell apoptosis. More studies are required to further investigate
the apoptosis of HTCFs seeded on coated magnesium alloy disks.

In Chapter 5, we performed the BrdU assay and detected the expression of α-SMA
proteins to examine the anti-proliferative potential of differently coated magnesium
alloys. In future studies, it would be useful to assess the expression of collagen-1 to
further explore the potential of coated magnesium alloys in inhibiting protein
expressions. RT-PCR may also be performed to determine whether coated magnesium
alloys could suppress mRNA synthesis.

6.3 Future directions
In this section, future directions are presented to address the identified limitations and
expand upon the findings of the current study. Continued study of the corrosion
resistance of magnesium alloys would be useful, especially if correlated to the effect
on the apoptosis of HTCFs, and their anti-proliferative potentials. Prototypes of
coated magnesium alloy-based glaucoma drainage device should be designed.
Based upon these designs, the size of the devices would permit determination of the
daily volume of hydrogen release, which experiments to determine the safe and
acceptable ranges..

Upon completion of the in vitro phase of these experiments, future animal studies
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would be designed.

Implantation of the coated magnesium alloy-based glaucoma

drainage device into the eyes of New Zealand rabbits would allow determination of
the effects on the tissue and organ. Parameters such as scar formation and
encapsulation, as well as the postoperative adverse events related to the corrosion
would be useful to obtain.

Anti-scarring will continue to be a focus of our future studies, and the release of
different ions from coatings will be assessed in a comprehensive fashion. For example,
matrix metalloproteinases proteins are associated with scar formation and regulated
by calcium ions
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. Based on the findings of the immersion test, it was found that

calcium ions were released from the coatings when they came in contact with body
fluids. Therefore, we speculate that the increased extracellular calcium concentration
may influence the expression of matrix metalloproteinases and scar formation, which
needs to be validated in further studies.

6.4 Concluding remarks
Magnesium alloy is a novel biodegradable material which possesses many
advantageous properties which may render it useful as a surgical adjunctive device.
These properties include: non-toxicity, high strength, light weight, and high biological
compatibility. Complications related to its corrosive properties caused it to lose
interest as a potential implantable device in the middle of the 20th century.
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More recent advancements in the area of coating technology have allowed the
synthesis of novel coated magnesium alloys, which have shown significant promise as
effective biodegradable materials. In this thesis the corrosive response of a selected
group of coated magnesium alloys was reported. Although the corrosion rates were
still relatively high, the ability of the coatings to differentially modulate these rates,
and reduce them in comparison to pure magnesium, was demonstrated.

Scarring caused by fibroblast proliferation is a major risk factor leading to glaucoma
surgery failure. In the process of degradation of coated magnesium alloys, different
ions are released, changing the pH of extracellular environment and thereby affecting
the proliferation of cells. In this study, cellular proliferation when treated by
differently coated magnesium alloys was examined, and the potential anti-scarring
properties were also investigated. The results showed that, when compared with
titanium, coated magnesium alloys could effectively inhibit the proliferation of
HTCFs and reduce the expression of myofibroblast specific antibodies.

6.5 Conclusions of full text
1. Coatings are able to effect the corrosive properties of magnesium.
2. HA was most resistant to corrosion.
3. No significant difference was found in metabolic activity or necrosis at different
times during the logarithmic phase of HTCFs.
4. DCPD+SA demonstrated a stronger ability to reduce metabolic activity while its
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cytotoxic profile was the same as titanium and glass.
5. In comparison to titanium, coated magnesium alloys attenuated HTCFs
proliferation.
6. Coated magnesium alloys reduced the expression of α-SMA.
7. The expression of α-SMA was significantly decreased in cells exposed to the HA
coated magnesium.

６１

7. References:
1.

Mubagwa K, Gwanyanya A, Zakharov S, Macianskiene R. Regulation of
cation channels in cardiac and smooth muscle cells by intracellular magnesium.
Archives of biochemistry and biophysics 2007; 458: 73-89.

2.

Ellahioui Y, Prashar S, Gomez-Ruiz S. A short overview on the biomedical
applications of silica, alumina and calcium phosphate-based nanostructured
materials. Current medicinal chemistry 2016.

3.

Okuma T. Magnesium and bone strength. Nutrition (Burbank, Los Angeles
County, Calif) 2001; 17: 679-80.

4.

Orchard TS, Larson JC, Alghothani N, Bout-Tabaku S, Cauley JA, Chen Z,
LaCroix AZ, Wactawski-Wende J, Jackson RD. Magnesium intake, bone
mineral density, and fractures: results from the Women's Health Initiative
Observational Study. The American journal of clinical nutrition 2014; 99:
926-33.

5.

Farsinejad-Marj M, Saneei P, Esmaillzadeh A. Dietary magnesium intake,
bone mineral density and risk of fracture: a systematic review and
meta-analysis. Osteoporosis international : a journal established as result of

６２

cooperation between the European Foundation for Osteoporosis and the
National Osteoporosis Foundation of the USA 2016; 27: 1389-99.

6.

Institute of Medicine Standing Committee on the Scientific Evaluation of
Dietary Reference I. The National Academies Collection: Reports funded by
National Institutes of Health. In.The National Academies Collection: Reports
funded by National Institutes of Health, Washington (DC): National
Academies Press (US) National Academy of Sciences., 1997.

7.

Takeda R, Nakamura T. Effects of high magnesium intake on bone mineral
status and lipid metabolism in rats. Journal of nutritional science and
vitaminology 2008; 54: 66-75.

8.

O'Brien B, Carroll W. The evolution of cardiovascular stent materials and
surfaces in response to clinical drivers: a review. Acta biomaterialia 2009; 5:
945-58.

9.

Mani G, Feldman MD, Patel D, Agrawal CM. Coronary stents: a materials
perspective. Biomaterials 2007; 28: 1689-710.

10.

Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium.

６３

An update on physiological, clinical and analytical aspects. Clinica chimica
acta; international journal of clinical chemistry 2000; 294: 1-26.

11.

Vormann J. Magnesium: nutrition and metabolism. Molecular aspects of
medicine 2003; 24: 27-37.

12.

Quigley HA. Number of people with glaucoma worldwide. British journal of
ophthalmology 1996; 80: 38-93.

13.

Atreides SP, Skuta GL, Reynolds AC. Wound healing modulation in glaucoma
filtering surgery. International ophthalmology clinics 2004; 44: 61-106.

14.

Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and
-beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation,
and migration. Investigative ophthalmology & visual science 2000; 41:
756-63.

15.

Huan ZG, Leeflang MA, Zhou J, Fratila-Apachitei LE, Duszczyk J. In vitro
degradation behavior and cytocompatibility of Mg-Zn-Zr alloys. Journal of
materials science Materials in medicine 2010; 21: 2623-35.

６４

16.

Hu C-Y, Matsuo H, Tomita G, Suzuki Y, Araie M, Shirato S, Tanaka S.
Clinical characteristics and leakage of functioning blebs after trabeculectomy
with mitomycin-C in primary glaucoma patients. Ophthalmology 2003; 110:
345-52.

17.

Lehmann OJ, Bunce C, Matheson MM, Maurino V, Khaw PT, Wormald R,
Barton

K.

Risk

factors

for

development

of

post-trabeculectomy

endophthalmitis. British journal of ophthalmology 2000; 84: 1349-53.

18.

Grillo CA, Alvarez F, Fernandez Lorenzo de Mele MA. Degradation of
bioabsorbable Mg-based alloys: Assessment of the effects of insoluble
corrosion products and joint effects of alloying components on mammalian
cells. Materials science & engineering C, Materials for biological
applications 2016; 58: 372-80.

19.

Walker J, Shadanbaz S, Woodfield TB, Staiger MP, Dias GJ. Magnesium
biomaterials for orthopedic application: a review from a biological perspective.
Journal of biomedical materials research Part B, Applied biomaterials 2014;
102: 1316-31.

20.

Hanzi AC, Gerber I, Schinhammer M, Loffler JF, Uggowitzer PJ. On the in
vitro and in vivo degradation performance and biological response of new

６５

biodegradable Mg-Y-Zn alloys. Acta biomaterialia 2010; 6: 1824-33.

21.

Kirkland NT, Birbilis N. Introduction to Magnesium Biomaterials.
In.Introduction to Magnesium Biomaterials: Springer, 2014; 1-12.

22.

Lambotte A. The Classic. Contribution to conservative surgery of the injured
hand. By Dr. A. Lambotte. 1928. Clinical orthopaedics and related research
1987: 4-6.

23.

Staiger MP, Pietak AM, Huadmai J, Dias G. Magnesium and its alloys as
orthopedic biomaterials: a review. Biomaterials 2006; 27: 1728-34.

24.

Zberg B, Uggowitzer PJ, Loffler JF. MgZnCa glasses without clinically
observable hydrogen evolution for biodegradable implants. Nature materials
2009; 8: 887-91.

25.

Gu X, Zheng Y, Cheng Y, Zhong S, Xi T. In vitro corrosion and
biocompatibility of binary magnesium alloys. Biomaterials 2009; 30: 484-98.

26.

Janning C, Willbold E, Vogt C, Nellesen J, Meyer-Lindenberg A, Windhagen
H, Thorey F, Witte F. Magnesium hydroxide temporarily enhancing osteoblast

６６

activity and decreasing the osteoclast number in peri-implant bone
remodelling. Acta biomaterialia 2010; 6: 1861-8.

27.

Yang JX, Cui FZ, Lee IS, Zhang Y, Yin QS, Xia H, Yang SX. In vivo
biocompatibility and degradation behavior of Mg alloy coated by calcium
phosphate in a rabbit model. Journal of biomaterials applications 2012; 27:
153-64.

28.

Witte F, Ulrich H, Palm C, Willbold E. Biodegradable magnesium scaffolds:
Part II: peri-implant bone remodeling. Journal of biomedical materials
research Part A 2007; 81: 757-65.

29.

Witte F, Ulrich H, Rudert M, Willbold E. Biodegradable magnesium scaffolds:
Part 1: appropriate inflammatory response. Journal of biomedical materials
research Part A 2007; 81: 748-56.

30.

Witte F, Feyerabend F, Maier P, Fischer J, Stormer M, Blawert C, Dietzel W,
Hort N. Biodegradable magnesium-hydroxyapatite metal matrix composites.
Biomaterials 2007; 28: 2163-74.

31.

Okazaki M. New type scaffold biomaterials with magnesium accelerating

６７

osteoblast adhesion and bone formation. Journal of Oral Tissue Engineering
2004; 1: 31-40

32.

Zreiqat H, Evans P, Howlett CR. Effect of surface chemical modification of
bioceramic on phenotype of human bone‐derived cells. Journal of biomedical
materials research 1999; 44: 389-96.29.

33.

Hunt J, Heggarty D. Application of microscopic methods for the detection of
cell attachment to polymers. Methods in molecular biology (Clifton, NJ) 2004;
238: 207-16.

34.

Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R.
Drug-eluting stent and coronary thrombosis: biological mechanisms and
clinical implications. Circulation 2007; 115: 1051-8.

35.

Bertrand OF, Sipehia R, Mongrain R, Rodes J, Tardif JC, Bilodeau L, Cote G,
Bourassa MG. Biocompatibility aspects of new stent technology. Journal of
the American College of Cardiology 1998; 32: 562-71.

36.

Heublein B, Rohde R, Kaese V, Niemeyer M, Hartung W, Haverich A.
Biocorrosion of magnesium alloys: a new principle in cardiovascular implant

６８

technology? Heart (British Cardiac Society) 2003; 89: 651-6.

37.

Waksman R, Pakala R, Kuchulakanti PK, Baffour R, Hellinga D, Seabron R,
Tio FO, Wittchow E, Hartwig S, Harder C, Rohde R, Heublein B, Andreae A,
Waldmann KH, Haverich A. Safety and efficacy of bioabsorbable magnesium
alloy stents in porcine coronary arteries. Catheterization and cardiovascular
interventions : official journal of the Society for Cardiac Angiography &
Interventions 2006; 68: 607-17; discussion 18-9.

38.

Zartner P, Cesnjevar R, Singer H, Weyand M. First successful implantation of
a biodegradable metal stent into the left pulmonary artery of a preterm baby.
Catheterization and cardiovascular interventions : official journal of the
Society for Cardiac Angiography & Interventions 2005; 66: 590-4.

39.

Di Mario C, Griffiths H, Goktekin O, Peeters N, Verbist J, Bosiers M, Deloose
K, Heublein B, Rohde R, Kasese V, Ilsley C, Erbel R. Drug-eluting
bioabsorbable magnesium stent. Journal of interventional cardiology 2004; 17:
391-5.

40.

Schranz D, Zartner P, Michel-Behnke I, Akinturk H. Bioabsorbable metal
stents for percutaneous treatment of critical recoarctation of the aorta in a

６９

newborn. Catheterization and cardiovascular interventions : official journal of
the Society for Cardiac Angiography & Interventions 2006; 67: 671-3.

41.

Mulla A, Massey KL, Kalra J. Vitreous humor biochemical constituents:
evaluation of between-eye differences. The American journal of forensic
medicine and pathology 2005; 26: 146-9.

42.

George GA, Heaton FW. Changes in cellular composition during magnesium
deficiency. The Biochemical journal 1975; 152: 609-15.

43.

Agarwal R, Iezhitsa L, Agarwal P. Pathogenetic role of magnesium deficiency
in ophthalmic diseases. Biometals : an international journal on the role of
metal ions in biology, biochemistry, and medicine 2013.

44.

Hatwal A, Gujral AS, Bhatia RP, Agrawal JK, Bajpai HS. Association of
hypomagnesemia with diabetic retinopathy. Acta ophthalmologica 1989; 67:
714-6.

45.

Mishima S. Clinical pharmacokinetics of the eye. Proctor lecture. Investigative
ophthalmology & visual science 1981; 21: 504-41.

７０

46.

Kirkpatrick H. The use of magnesium sulphate as a local application in
inflammation of the conjunctiva and cornea. The British journal of
ophthalmology 1920; 4: 281.

47.

Bachman WG, Wilson G. Essential ions for maintenance of the corneal
epithelial surface. Investigative ophthalmology & visual science 1985; 26:
1484-8.

48.

Hogan ZS, Brown KL, Ishola A, Gatimu J, Flucker L, Huff JW. Effects of
divalent cations on bovine corneal stromal swelling rates. Current eye
research 2008; 33: 677-82.

49.

Gong H, Amemiya T, Takaya K. Retinal changes in magnesium-deficient rats.
Experimental eye research 2001; 72: 23-32.

50.

Thalasselis A. The possible relationship between keratoconus and magnesium
deficiency. Ophthalmic & physiological optics : the journal of the British
College of Ophthalmic Opticians (Optometrists) 2005; 25: 7-12.

51.

Andreassen TT, Simonsen AH, Oxlund H. Biomechanical properties of
keratoconus and normal corneas. Experimental eye research 1980; 31: 435-41.

７１

52.

Aktekin M, Sargon MF, Cakar P, Celik HH, Firat E. Ultrastructure of the
cornea epithelium in keratoconus. Okajimas folia anatomica Japonica 1998;
75: 45-53.

53.

Sawaguchi S, Fukuchi T, Abe H, Kaiya T, Sugar J, Yue BY. Three-dimensional
scanning electron microscopic study of keratoconus corneas. Archives of
ophthalmology (Chicago, Ill : 1960) 1998; 116: 62-8.

54.

Pouliquen Y, Graf B, Hamada R, Giraud JP, Offret G. [Fibrocytes in
keratoconus. Morphological aspect and modification of the extra-cellular
space. Study with light and electron microscopy]. Archives d'ophtalmologie et
revue generale d'ophtalmologie 1972; 32: 571-86.

55.

Dilsiz N, Olcucu A, Atas M. Determination of calcium, sodium, potassium and
magnesium concentrations in human senile cataractous lenses. Cell
biochemistry and function 2000; 18: 259-62.

56.

Agarwal R, Iezhitsa I, Agarwal P, Spasov A. Magnesium deficiency: does it
have a role to play in cataractogenesis? Exp Eye Res 2012; 101: 82-9.

７２

57.

Agarwal R, Iezhitsa I, Awaludin NA, Ahmad Fisol NF, Bakar NS, Agarwal P,
Abdul Rahman TH, Spasov A, Ozerov A, Mohamed Ahmed Salama MS,
Mohd Ismail N. Effects of magnesium taurate on the onset and progression of
galactose-induced experimental cataract: in vivo and in vitro evaluation. Exp
Eye Res 2013; 110: 35-43.

58.

Nagai N, Fukuhata T, Ito Y. Effect of magnesium deficiency on intracellular
ATP levels in human lens epithelial cells. Biological & pharmaceutical
bulletin 2007; 30: 6-10.

59.

Nagai N, Ito Y, Inomata M, Shumiya S, Tai H, Hataguchi Y, Nakagawa K.
Delay of cataract development in the Shumiya cataract rat by the
administration of drinking water containing high concentration of magnesium
ion. Biological & pharmaceutical bulletin 2006; 29: 1234-8.

60.

Agarwal R, Iezhitsa IN, Agarwal P, Spasov AA. Mechanisms of
cataractogenesis in the presence of magnesium deficiency. Magnesium
research 2013; 26: 2-8.

61.

Kao CL, Chou CK, Tsai DC, Hsu WM, Liu JH, Wang CS, Lin JC, Wu CC,
Peng CH, Chang CJ, Kao CL, Chiou SH. Nitric oxide levels in the aqueous

７３

humor in cataract patients. Journal of cataract and refractive surgery 2002; 28:
507-12.

62.

Ornek K, Karel F, Buyukbingol Z. May nitric oxide molecule have a role in
the pathogenesis of human cataract? Exp Eye Res 2003; 76: 23-7.

63.

Retamal MA, Yin S, Altenberg GA, Reuss L. Modulation of Cx46
hemichannels by nitric oxide. American journal of physiology Cell physiology
2009; 296: C1356-63.

64.

Carafoli E. The Ca2+ pump of the plasma membrane. J Biol Chem 1992; 267:
2115-8.

65.

Hulsman CA, Vingerling JR, Hofman A, Witteman JC, de Jong PT. Blood
pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study.
Archives of ophthalmology (Chicago, Ill : 1960) 2007; 125: 805-12.

66.

Bonomi L, Marchini G, Marraffa M, Bernardi P, Morbio R, Varotto A.
Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt
Study. Ophthalmology 2000; 107: 1287-93.

７４

67.

Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of
long-term progression in the early manifest glaucoma trial. Ophthalmology
2007; 114: 1965-72.

68.

Wang M, Tashiro M, Berlin JR. Regulation of L-type calcium current by
intracellular magnesium in rat cardiac myocytes. The Journal of physiology
2004; 555: 383-96.

69.

Howarth FC, Levi AJ. Internal free magnesium modulates the voltage
dependence of contraction and Ca transient in rabbit ventricular myocytes.
Pflugers Archiv : European journal of physiology 1998; 435: 687-98.

70.

Ishiguro S, Matsuyama T, Sakaguchi H, Nishio A. Ex vivo study of the
increased sensitivity to NO of endothelium-denuded thoracic aortas isolated
from dietary magnesium-deficient rats. Magnesium research 1997; 10: 21-31.

71.

Laurant P, Touyz RM. Physiological and pathophysiological role of
magnesium in the cardiovascular system: implications in hypertension.
Journal of hypertension 2000; 18: 1177-91.

72.

Teragawa H, Kato M, Yamagata T, Matsuura H, Kajiyama G. Magnesium

７５

causes nitric oxide independent coronary artery vasodilation in humans. Heart
(British Cardiac Society) 2001; 86: 212-6.

73.

Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M. Oral
magnesium supplementation improves vascular function in elderly diabetic
patients. Magnesium research 2010; 23: 131-7.

74.

Soltani N, Keshavarz M, Sohanaki H, Zahedi Asl S, Dehpour AR. Relaxatory
effect of magnesium on mesenteric vascular beds differs from normal and
streptozotocin induced diabetic rats. European journal of pharmacology 2005;
508: 177-81.

75.

Kumar AR, Kurup PA. Inhibition of membrane Na+-K+ ATPase activity: a
common pathway in central nervous system disorders. The Journal of the
Association of Physicians of India 2002; 50: 400-6.

76.

Sugiyama T, Moriya S, Oku H, Azuma I. Association of endothelin-1 with
normal tension glaucoma: clinical and fundamental studies. Survey of
ophthalmology 1995; 39 Suppl 1: S49-56.

77.

Kaiser HJ, Flammer J, Graf T, Stümpfig D. Systemic blood pressure in

７６

glaucoma

patients.

Graefe's

archive

for

clinical

and

experimental

ophthalmology 1993; 231: 677-80.

78.

Winterkorn JM. The influence of magnesium on visual field and peripheral
vasospasm in glaucoma. Survey of ophthalmology 1995; 40: 83-4.

79.

McMenimen KA, Dougherty DA, Lester HA, Petersson EJ. Probing the Mg2+
blockade site of an N-methyl-D-aspartate (NMDA) receptor with unnatural
amino acid mutagenesis. ACS chemical biology 2006; 1: 227-34.

80.

Mark LP, Prost RW, Ulmer JL, Smith MM, Daniels DL, Strottmann JM,
Brown WD, Hacein-Bey L. Pictorial review of glutamate excitotoxicity:
fundamental concepts for neuroimaging. AJNR American journal of
neuroradiology 2001; 22: 1813-24.

81.

Decollogne S, Tomas A, Lecerf C, Adamowicz E, Seman M. NMDA receptor
complex blockade by oral administration of magnesium: comparison with
MK-801. Pharmacology, biochemistry, and behavior 1997; 58: 261-8.

82.

Lambuk L, Jafri AJ, Arfuzir NN, Iezhitsa I, Agarwal R, Rozali KN, Agarwal P,
Bakar NS, Kutty MK, Yusof AP, Krasilnikova A, Spasov A, Ozerov A, Ismail

７７

NM.

Neuroprotective

Effect

of

Magnesium

Acetyltaurate

Against

NMDA-Induced Excitotoxicity in Rat Retina. Neurotoxicity research 2016.

83.

Carafoli E. Calcium--a universal carrier of biological signals. Delivered on 3
July 2003 at the Special FEBS Meeting in Brussels. The FEBS journal 2005;
272: 1073-89.

84.

Blaylock RL. Food additive excitotoxins and degenerative brain disorders.
Medical Sentinel 1999; 4: 212-5.

85.

Sun MH, Pang JH, Chen SL, Han WH, Ho TC, Chen KJ, Kao LY, Lin KK,
Tsao

YP.

Retinal

protection

from

acute

glaucoma-induced

ischemia-reperfusion injury through pharmacologic induction of heme
oxygenase-1. Investigative ophthalmology & visual science 2010; 51:
4798-808.

86.

Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J,
Singel DJ, Stamler JS. A redox-based mechanism for the neuroprotective and
neurodestructive effects of nitric oxide and related nitroso-compounds. Nature
1993; 364: 626-32.

７８

87.

Suschek CV, Kolb H, Kolb-Bachofen VV. Effects of Magnesium Dobesilate
on Nitric Oxide Synthase Activity in Endothelial Cells. The International
journal of angiology : official publication of the International College of
Angiology, Inc 1999; 8: 21-4.

88.

Sun X, Mei Y, Tong E. Effect of magnesium on nitric oxide synthase of
neurons in cortex during early period of cerebral ischemia. Journal of Tongji
Medical University = Tong ji yi ke da xue xue bao 2000; 20: 13-5, 42.

89.

Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field
and

peripheral

vasospasm

in

glaucoma.

Ophthalmologica

Journal

international d'ophtalmologie International journal of ophthalmology
Zeitschrift fur Augenheilkunde 1995; 209: 11-3.

90.

Aydin B, Onol M, Hondur A, Kaya MG, Ozdemir H, Cengel A, Hasanreisoglu
B. The effect of oral magnesium therapy on visual field and ocular blood flow
in normotensive glaucoma. European journal of ophthalmology 2010; 20:
131-5.

91.

Troncoso MU. Cyclodialysis with insertion of a metal implant in the treatment
of glaucoma: A preliminary report. Archives of Ophthalmology 1940; 23:

７９

270-300.

92.

Boshoff P. Use of troncoso’s magnesium implant in cyclodialysis for relief
of glaucoma: observations in two cases. Archives of Ophthalmology 1945; 33:
404.

93.

Moravej M, Mantovani D. Biodegradable metals for cardiovascular stent
application: interests and new opportunities. International journal of
molecular sciences 2011; 12: 4250-70.

94.

Staiger MP, Pietak AM, Huadmai J, Dias G. Magnesium and its alloys as
orthopedic biomaterials: a review. Biomaterials 2006; 27: 1728-34.

95.

Zeng R, Dietzel W, Witte F, Hort N, Blawert C. Progress and challenge for
magnesium alloys as biomaterials. Advanced Engineering Materials 2008; 10:
B3-B14.

96.

Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija
K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed
healing and late thrombotic risk. Journal of the American College of
Cardiology 2006; 48: 193-202.

８０

97.

Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J,
Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap
SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD.
Hypersensitivity cases associated with drug-eluting coronary stents: a review
of available cases from the Research on Adverse Drug Events and Reports
(RADAR) project. Journal of the American College of Cardiology 2006; 47:
175-81.

98.

Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials
comparing drug-eluting vs. bare metal stents in coronary artery disease: a
meta-analysis. European heart journal 2006; 27: 2784-814.

99.

Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP,
Sianos G, Ligthart JM, van Essen D, de Feyter PJ, Serruys PW. Indication of
long-term endothelial dysfunction after sirolimus-eluting stent implantation.
European heart journal 2006; 27: 166-70.

100.

Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P,
Haude M, Heublein B, Horrigan M, Ilsley C, Bose D, Koolen J, Luscher TF,
Weissman N, Waksman R. Temporary scaffolding of coronary arteries with

８１

bioabsorbable magnesium stents: a prospective, non-randomised multicentre
trial. Lancet (London, England) 2007; 369: 1869-75.

101.

Bourne RR, Taylor HR, Flaxman SR, Keeffe J, Leasher J, Naidoo K, Pesudovs
K, White RA, Wong TY, Resnikoff S, Jonas JB. Number of People Blind or
Visually Impaired by Glaucoma Worldwide and in World Regions 1990 - 2010:
A Meta-Analysis. PloS one 2016; 11: e0162229.

102.

Quigley HA. Proportion of those with open-angle glaucoma who become
blind. Ophthalmology 1999; 106: 2039-41.

103.

Quigley HA, Broman AT. The number of people with glaucoma worldwide in
2010 and 2020. The British journal of ophthalmology 2006; 90: 262-7.

104. American Academy of Ophthalmology Preferred Practice Patterns Committee
GP.

Preferred

practice

pattern:

primary

open-angle

glaucoma.

In: Ophthalmology. Chicago, Illinois: American Academy of Ophtalmology:
2010.

105.

Singh K, Mehta K, Shaikh NM, Tsai JC, Moster MR, Budenz DL, Greenfield
DS, Chen PP, Cohen JS, Baerveldt GS. Trabeculectomy with intraoperative
mitomycin C versus 5-fluorouracil: prospective randomized clinical trial.

８２

Ophthalmology 2000; 107: 2305-9.

106.

Skuta GL, Beeson CC, Higginbotham EJ, Lichter PR, Musch DC, Bergstrom
TJ, Klein TB, Falck FY. Intraoperative mitomycin versus postoperative
5-fluorouracil in high-risk glaucoma filtering surgery. Ophthalmology 1992;
99: 438-44.

107.

Khaw P. Advances in glaucoma surgery: evolution of antimetabolite
adjunctive therapy. Journal of glaucoma 2001; 10: S81-S4.

108.

Scott IU, Greenfield DS, Schiffman J, Nicolela MT, Rueda JC, Tsai JC,
Palmberg PF. Outcomes of primary trabeculectomy with the use of adjunctive
mitomycin. Archives of Ophthalmology 1998; 116: 286-91.

109.

Hu C-Y, Matsuo H, Tomita G, Suzuki Y, Araie M, Shirato S, Tanaka S.
Clinical characteristics and leakage of functioning blebs after trabeculectomy
with mitomycin-C in primary glaucoma patients. Ophthalmology 2003; 110:
345-52.

110.

Lehmann OJ, Bunce C, Matheson MM, Maurino V, Khaw PT, Wormald R,
Barton

K.

Risk

factors

for

development

of

post-trabeculectomy

endophthalmitis. British journal of ophthalmology 2000; 84: 1349-53.

８３

111.

Cipriano AF, Sallee A, Tayoba M, Cortez Alcaraz MC, Lin A, Guan RG, Zhao
ZY, Liu H. Cytocompatibility and early inflammatory response of human
endothelial cells in direct culture with Mg-Zn-Sr alloys. Acta biomaterialia
2016.

112.

Hanzi AC, Gerber I, Schinhammer M, Loffler JF, Uggowitzer PJ. On the in
vitro and in vivo degradation performance and biological response of new
biodegradable Mg-Y-Zn alloys. Acta biomaterialia 2010; 6: 1824-33.

113.

Huan ZG, Leeflang MA, Zhou J, Fratila-Apachitei LE, Duszczyk J. In vitro
degradation behavior and cytocompatibility of Mg-Zn-Zr alloys. Journal of
materials science Materials in medicine 2010; 21: 2623-35.

114.

Kramer M, Schilling M, Eifler R, Hering B, Reifenrath J, Besdo S, Windhagen
H, Willbold E, Weizbauer A. Corrosion behavior, biocompatibility and
biomechanical stability of a prototype magnesium-based biodegradable
intramedullary nailing system. Materials science & engineering C, Materials
for biological applications 2016; 59: 129-35.

115.

Grotendorst GR. Connective tissue growth factor: a mediator of TGF-beta
action on fibroblasts. Cytokine & growth factor reviews 1997; 8: 171-9.

８４

116.

Yu DY, Morgan WH, Sun X, Su EN, Cringle SJ, Yu PK, House P, Guo W, Yu
X. The critical role of the conjunctiva in glaucoma filtration surgery. Progress
in retinal and eye research 2009; 28: 303-28.

117.

Grewe PH, Deneke T, Machraoui A, Barmeyer J, Muller KM. Acute and
chronic tissue response to coronary stent implantation: pathologic findings in
human specimen. Journal of the American College of Cardiology 2000; 35:
157-63.

118.

Zhao Y, Wong SM, Wong HM, Wu S, Hu T, Yeung KW, Chu PK. Effects of
carbon and nitrogen plasma immersion ion implantation on in vitro and in vivo
biocompatibility of titanium alloy. ACS applied materials & interfaces 2013; 5:
1510-6.

119.

Hatwal A, Gujral A, Bhatia R, Agrawal J, Bajpai H. Association of
hypomagnesemia with diabetic retinopathy. Acta ophthalmologica 1989; 67:
714-6.

120.

Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker.
American heart journal 1984; 108: 188-93.

８５

121.

Levine BS, Coburn JW. Magnesium, the mimic/antagonist of calcium.
In.Magnesium, the mimic/antagonist of calcium: Mass Medical Soc, 1984.

122. Aydin B, Onol M, Hondur A, Kaya M, Ozdemir H, Cengel A, Hasanreisoglu B.
The effect of oral magnesium therapy on visual field and ocular blood flow in
normotensive glaucoma. European journal of ophthalmology 2009; 20: 131-5

123.

Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field
and peripheral vasospasm in glaucoma. Ophthalmologica 1995; 209: 11-3.

124.

Ekici F, Korkmaz Ş, Karaca EE, Sül S, Tufan HA, Aydın B, Dileköz E. The
role of magnesium in the pathogenesis and treatment of glaucoma.
International Scholarly Research Notices 2014; 2014.

125.

Yang J, Cui F, Lee IS. Surface modifications of magnesium alloys for
biomedical applications. Annals of biomedical engineering 2011; 39: 1857-71.

126.

Agarwal R, Agarwal P. Pathogenetic role of magnesium deficiency in
ophthalmic diseases. Biometals 2014; 27: 5-18.

127.

Hornberger H, Virtanen S, Boccaccini A. Biomedical coatings on magnesium
alloys–a review. Acta biomaterialia 2012; 8: 2442-55

８６

128.

Waterman

J,

Staiger

M.

Coating

systems

for

magnesium-based

biomaterials-state of the art. Magnesium technology 2011.

129. Barrere F. Biomimetic calcium phosphate coatings: physicochemistry and
biological activity: University of Twente, 2002.

130.

Gross UM, Lassner D. In vitro and in vivo evaluation of thin calcium
phosphate coatings. In.In vitro and in vivo evaluation of thin calcium
phosphate coatings: Springer, 2009; 67-99.

131.

Staiger MP, Pietak AM, Huadmai J, Dias G. Magnesium and its alloys as
orthopedic biomaterials: a review. Biomaterials 2006; 27: 1728-34.

132.

Natarajan S, Sivan V, Tennyson PG, Kiran VR. Protective coatings on
magnesium and its alloys: a critical review. Corrosion Prevention and Control
2004; 51: 142-63.

133.

Guo KW. A review of magnesium/magnesium alloys corrosion and its
protection. Recent Pat Corros Sci 2010; 2: 13-21.

８７

134. Hornberger H, Virtanen S, Boccaccini A. Biomedical coatings on magnesium
alloys–a review. Acta biomaterialia 2012; 8: 2442-55.

135. E. Erbe, J. Marx, T. Clineff, L. Bellincampi, Eur. Spine J. 2010;10 :141-146.

136.

H.L. Dai, X.Y. Wang, Y.C. Han, X. Jiang, S.P. Li, J. Mater. Sci.Tech.
2011;27 :431-436

137. Ghosh S, Nandi S, Kundu B, Datta S, De D, Roy S, Basu D. Interfacial
response of hydroxyapatite and tri-calcium phosphate prepared by a novel
aqueous combustion method: A comparison with bioglass in vivo implanted in
goat. J Biomed Mater Res B 2008; 86: 217-27

138.

Zeng R, Dietzel W, Witte F, Hort N, Blawert C. Progress and challenge for
magnesium alloys as biomaterials. Advanced Engineering Materials 2008; 10.

139.

Müller WD, Nascimento ML, Zeddies M, Córsico M, Gassa LM, Mele
MAFLd. Magnesium and its alloys as degradable biomaterials: corrosion
studies using potentiodynamic and EIS electrochemical techniques. Materials
Research 2007; 10: 5-10.

140.

Kirkland NT. Magnesium biomaterials: past, present and future. Corrosion
Engineering, Science and Technology 2012; 47: 322-8

８８

141.

Fulmer M T，Brown P W．J．J Mater Sci-Mater M，1998，9: 197-202．

142.

Burguera E F, Guitian F, chow L C. J. Key Eng Mat，2005, 284-286; 15-18.

143. Grover L M. Knowles J C, Fleming G J P. et al. J. J Biomaterials, 2003.
24:4133-4141.

144.

Gurrappa I. Corrosion and its importance in selection of materials for
biomedical applications. Corrosion Prevention & Control 2001; 48: 23-37.

145. Rashmir‐Raven A, Richardson D, Aberman H, De Young D. The response of
cancellous and cortical canine bone to hydroxylapatite‐coated and uncoated
titanium rods. Journal of Applied Biomaterials 1995; 6: 237-42.

146. Chen Fenghua，Ma Jianmin，Wang Ningli，Wang Jinjin. Culture of the human
Tenon’s capsule fibroblast cells in vitro. J Otolaryngol Ophthal Shandong
University 2008；22：350-355.

147.

Lorenz C, Brunner JG, Kollmannsberger P, Jaafar L, Fabry B, Virtanen S.
Effect of surface pre-treatments on biocompatibility of magnesium. Acta
Biomaterialia 2009; 5: 2783-9.

８９

148.

Fischer J, Pröfrock D, Hort N, Willumeit R, Feyerabend F. Reprint of:
Improved cytotoxicity testing of magnesium materials. Materials Science and
Engineering: B 2011; 176: 1773-7

149. V.A. Dubok, Powder Metal. Met. Ceramic 2000;39:381-394.

150. Souza C, Tran DH, Loman J, Law SK, Coleman AL, Caprioli J. Long-term
outcomes of Ahmed glaucoma valve implantation in refractory glaucomas.
American journal of ophthalmology 2007; 144: 893-900.

151. Patel S, Pasquale LR. Glaucoma drainage devices: a review of the past, present,
and future. In.Glaucoma drainage devices: a review of the past, present, and
future, Vol. 25: Taylor & Francis, 2010; 265-70.

152.

Guo Sa, DiPietro LA. Factors affecting wound healing. Journal of dental
research 2010; 89: 219-29.

153. Ayyala RS, Harman LE, Michelini-Norris B, Ondrovic LE, Haller E, Margo
CE, Stevens SX. Comparison of different biomaterials for glaucoma drainage
devices. Archives of Ophthalmology 1999; 117: 233-6.

９０

154. Hinz B. Formation and function of the myofibroblast during tissue repair.
Journal of Investigative Dermatology 2007; 127: 526-37.

155. Jordan DR, Gilberg S, Bawazeer A. Coralline hydroxyapatite orbital implant
(bio-eye): experience with 158 patients. Ophthalmic Plastic & Reconstructive
Surgery 2004; 20: 69-74.

156.

LeBleu VS, Taduri G, O'connell J, Teng Y, Cooke VG, Woda C, Sugimoto H,
Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nature
medicine 2013; 19: 1047-53

157.

Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of
metalloproteinases. Circulation research 2003; 92: 827-39.

９１

Curriculum Vitae

Personal information:
Name: Xiangji Li
Gender：Male

Education:
M.D, Third Military Medical University, 2001-2006
Master Science，Ophthalmology，Third Military Medical University, 2010-2013
PHD candidate, Ophthalmology，Third Military Medical University, 2015MSc Surgery，Ophthalmology，The University of Western Ontario, 2016-2017

Employment and workshops:
Residency：
July 2006-Oct 2007 ， Finished residency training programs at department of
Cardiovascular,

Neurosurgery and Otolaryngology

Oct 2007-Apr 2008，Major in glaucoma
May 2008-Oct 2008，Major in lens and cataract
Nov 2008-Feb 2009，Major in strabismus and pediatric
Mar 2009-Sept 2009，Major in retina and vitreous
Oct 2009-Apr 2010，Major in obit，eyelids and lacrimal system
May 2010-sept 2010，Major in external and corneal
Sept 2010-may 2012，Major in glaucoma

９２

Specialist：
May 2012-， Major in glaucoma，finished the research of “Risk factor analyze and
prevention research of postoperative Ⅲdegree shallow anterior chamber after glaucoma
filtration surgery”

Publications:
First author
1. Xiang-ji Li , Xiang-ge He. An Adams-Stokes syndrome case caused by local utility
of β-blocker eye drop. Chinese Modern Pharmacological Applications 2009，3（17）：
143.

2. Xiang-ji Li , Qiang Sun. Common problems and related countermeasures on
medical students during ophthalmological internship. Medical information. 2010.23
（5）：1183-1185.

3. Xiang-ji Li , Wei Wang, Junqi Liu. Genetics research and treatment progress on
LEBER's optic hereditary neuropathy.

The column of health: academic version.

2010，（11）：140-140

4. Xiang-ji Li ,Qiang Sun Xiang-ge He. Comparison and analysis between two
conjunctiva incisions and procedures for strabismus surgery learners. Chinese journal
of strabismus and pediatric ophthalmology. 2011，（1）：29-30

９３

5. Xiang-ji Li , Xiang-ge He. Bulbar conjunctiva foreign body granuloma caused by
stitches in palpebral conjunctiva (case report). Chinese Journal of Ophthalmology.
2012，48（7）：645

6. Xiang-ji Li , Xiang-ge He, Lin Xie. Clinical data analysis of 2744 hospitalized
glaucoma patients. Chinese Journal of Practical Ophthalmology. 2013，31（6）：
796-799

7. Xiangji Li, Xie Lin, Fusheng Pan,Yong Wang, Hong Liu,Yurong Tang, Cindy ML
Hutnik. A feasibility study of using biodegradable magnesium alloy in glaucoma
drainage device. International Journal of Ophthalmology. Manuscript in publication.

Corresponding author
1. Xiao Zheng，Wei Wang，Jun-qi Liu，Xiang-ji Li. Postoperative recurrence rate
between pterygium excision with free conjunctival autograft and traditional operation
treatment. Practical journal of clinic medicine.2014,11(1):119-120

2. Hai-yan Wang，Li-yong Chen，Wei Wang，Xiang-ji Li.Observation of oculocardiac
reflex during ophthalmectomy surgery with different anesthesia.Chongqing
medicine.2014，43（12）：126-128

９４

